<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Formulation Research]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[丹皮酚缓释片的制备工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:31</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[兰保强<sup>1</sup>,饶伟源<sup>1</sup>,邓聿胤<sup>1</sup>,邓志坚<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>兰保强<sup>1</sup>,饶伟源<sup>1</sup>,邓聿胤<sup>1</sup>,邓志坚<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309015&flag=1]]></guid><cfi:id>172</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[热熔挤出技术制备吡罗昔康固体分散体]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:31</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[张庆刚,赵星星]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张庆刚,赵星星</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309016&flag=1]]></guid><cfi:id>171</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[葛根汤颗粒一步制粒工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:31</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[黄京山,李伟,任尊华,王玉广]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>黄京山,李伟,任尊华,王玉广</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309017&flag=1]]></guid><cfi:id>170</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[褪黑素缓释片的制备及稳定性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[孙英<sup>1,2</sup>,黄桂华<sup>1</sup>,王海<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙英<sup>1,2</sup>,黄桂华<sup>1</sup>,王海<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308015&flag=1]]></guid><cfi:id>169</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[雷帕霉素药物支架稳定性试验研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[慈洪丽<sup>1</sup>,姜启凤<sup>2</sup>,王冰<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>慈洪丽<sup>1</sup>,姜启凤<sup>2</sup>,王冰<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308016&flag=1]]></guid><cfi:id>168</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[非那雄胺分散片的研制及体外溶出研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:36</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[郭洪涛,郭增光,马儒]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郭洪涛,郭增光,马儒</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307008&flag=1]]></guid><cfi:id>167</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[吡喹酮缓释植入剂的研制]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[马丽霞<sup>1</sup>,陈伟利<sup>2</sup>,刘阳<sup>1</sup>,王传栋<sup>1</sup>,王勤<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>马丽霞<sup>1</sup>,陈伟利<sup>2</sup>,刘阳<sup>1</sup>,王传栋<sup>1</sup>,王勤<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306014&flag=1]]></guid><cfi:id>166</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[雷贝拉唑钠肠溶片处方工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[郭增光,郭洪涛]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郭增光,郭洪涛</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306015&flag=1]]></guid><cfi:id>165</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[阿司匹林分散片的制备]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[程新德<sup>1,2</sup>,刘秀萍<sup>3</sup>,臧恒昌<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>程新德<sup>1,2</sup>,刘秀萍<sup>3</sup>,臧恒昌<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305014&flag=1]]></guid><cfi:id>164</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[盐酸左西替利嗪口崩片的处方工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[陈美丽,曹淑忠,邵长健]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈美丽,曹淑忠,邵长健</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305015&flag=1]]></guid><cfi:id>163</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[法罗培南钠缓释微丸的制备及体外释放特性考察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[赵利枝,陈小伟,郝贵周]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵利枝,陈小伟,郝贵周</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305016&flag=1]]></guid><cfi:id>162</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[胞磷胆碱钠片的制备与质量标准建立]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:02</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[赵先亮<sup>1,2,3</sup>,王世立<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵先亮<sup>1,2,3</sup>,王世立<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304018&flag=1]]></guid><cfi:id>161</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[布洛芬缓释胶囊释放度一致性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[赵丽,贺秀婷,皇甫传青,刘云]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵丽,贺秀婷,皇甫传青,刘云</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304019&flag=1]]></guid><cfi:id>160</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[富马酸氯马斯汀分散片的研制与质量控制]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[焦守宗]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>焦守宗</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304020&flag=1]]></guid><cfi:id>159</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方黄连素片质量分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:56</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[林林,林永强,汪冰,郭东晓,臧远芳,徐丽华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>林林,林永强,汪冰,郭东晓,臧远芳,徐丽华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303019&flag=1]]></guid><cfi:id>158</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射用盐酸吉西他滨处方工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[李晓昕<sup>1</sup>,朱磊<sup>1</sup>,吴宏坚<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李晓昕<sup>1</sup>,朱磊<sup>1</sup>,吴宏坚<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303020&flag=1]]></guid><cfi:id>157</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[挤出滚圆法制备盐酸索他洛尔骨架缓释微丸]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[曹淑忠<sup>1</sup>,陈美丽<sup>1</sup>,李美<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>曹淑忠<sup>1</sup>,陈美丽<sup>1</sup>,李美<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303021&flag=1]]></guid><cfi:id>156</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[二甲双胍丝素微球的制备工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[杨道伟,王厚伟,田景振]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨道伟,王厚伟,田景振</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302014&flag=1]]></guid><cfi:id>155</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[枸橼酸莫沙必利糖浆的制备及质量控制]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[孙秀芹,隋海超]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙秀芹,隋海超</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302015&flag=1]]></guid><cfi:id>154</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[银杏酮酯自乳化软胶囊的制备及质量评价]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:42</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[张恒玉<sup>1</sup>,杨莹<sup>2</sup>,张琳<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张恒玉<sup>1</sup>,杨莹<sup>2</sup>,张琳<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301011&flag=1]]></guid><cfi:id>153</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[盐酸莫西沙星搽剂的制备及质量控制]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:42</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[隋海超,崔芹芹,孙秀芹]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>隋海超,崔芹芹,孙秀芹</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301012&flag=1]]></guid><cfi:id>152</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[双氯芬酸钠滴眼液刺激性的缓解]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[孙刚,岳立群,王晨霞]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙刚,岳立群,王晨霞</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301013&flag=1]]></guid><cfi:id>151</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[感冒清热泡腾颗粒的制备工艺]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[孙萌,周长征]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙萌,周长征</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312011&flag=1]]></guid><cfi:id>150</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[尼美舒利脂质体的制备及质量评价初步研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[张娜娜<sup>1</sup>,陈新梅<sup>1</sup>,战旗<sup>2</sup>,王蕊<sup>2</sup>,刘青<sup>1</sup>,王萃<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张娜娜<sup>1</sup>,陈新梅<sup>1</sup>,战旗<sup>2</sup>,王蕊<sup>2</sup>,刘青<sup>1</sup>,王萃<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311016&flag=1]]></guid><cfi:id>149</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[拉西地平滴丸的制剂工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[韩克忠]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩克忠</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311017&flag=1]]></guid><cfi:id>148</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[富马酸氯马斯汀搽剂的制备与质量控制]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[焦守宗]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>焦守宗</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311018&flag=1]]></guid><cfi:id>147</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[丝素空白微球的制备]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:59</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[杨道伟]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨道伟</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310016&flag=1]]></guid><cfi:id>146</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[光阻法检查冻干粉针剂不溶性微粒的影响因素分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:50</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[李明慧,满春兰,郭明娟,夏肖丽,吴彦丽,李锐]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李明慧,满春兰,郭明娟,夏肖丽,吴彦丽,李锐</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409010&flag=1]]></guid><cfi:id>145</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[α-常春藤皂苷丙烯酸树脂L100-55纳米粒的制备及体外评价]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:29</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[李颖<sup>1,2</sup>,尹红然<sup>1</sup>,耿丽娟<sup>1</sup>,游本刚<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李颖<sup>1,2</sup>,尹红然<sup>1</sup>,耿丽娟<sup>1</sup>,游本刚<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408011&flag=1]]></guid><cfi:id>144</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[不同促透剂对人参皂苷Rg1体外透皮吸收的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[韩莉,王平,刘善新,苏酩,孙虎]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩莉,王平,刘善新,苏酩,孙虎</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407008&flag=1]]></guid><cfi:id>143</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[盐酸丁咯地尔滴剂的制备及质量分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[魏培<sup>1</sup>,曹春泉<sup>2</sup>,宋冶萍<sup>1</sup>,孙新堂<sup>1</sup>,杨瑞锋<sup>1</sup>,肖华平<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>魏培<sup>1</sup>,曹春泉<sup>2</sup>,宋冶萍<sup>1</sup>,孙新堂<sup>1</sup>,杨瑞锋<sup>1</sup>,肖华平<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407009&flag=1]]></guid><cfi:id>142</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[脉络宁注射液与溶媒的配伍稳定性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[宋杰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宋杰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407010&flag=1]]></guid><cfi:id>141</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基于壳聚寡糖的黄芩苷固体分散体的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:17</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[翟文婷,史红军]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>翟文婷,史红军</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406012&flag=1]]></guid><cfi:id>140</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[泮托拉唑钠肠溶微丸胶囊的处方工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[宋成刚,李洪程,王耀鹏,刘彬,单波,李国亮]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宋成刚,李洪程,王耀鹏,刘彬,单波,李国亮</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405010&flag=1]]></guid><cfi:id>139</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[奥利司他片的制备及体外溶出度考察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:19</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[崔健,陈小伟,郝贵周]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>崔健,陈小伟,郝贵周</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404009&flag=1]]></guid><cfi:id>138</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[氟比洛芬聚丙烯酸树脂RL/RS固体分散体的制备]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:01:00</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[刘善峰<sup>1</sup>,徐爱霞<sup>2</sup>,李叶桓<sup>3</sup>,王海龙<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘善峰<sup>1</sup>,徐爱霞<sup>2</sup>,李叶桓<sup>3</sup>,王海龙<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403011&flag=1]]></guid><cfi:id>137</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[参芪生血颗粒的制备及质量研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:01:00</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[徐晓艳,梁永广,贾光伟]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>徐晓艳,梁永广,贾光伟</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403012&flag=1]]></guid><cfi:id>136</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方黄芩苷凝胶的制备及质量控制研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[薄明香,成文娜,汪风芹,孙迎东]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>薄明香,成文娜,汪风芹,孙迎东</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402014&flag=1]]></guid><cfi:id>135</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[国产与进口恩替卡韦的比较研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[王海英<sup>1,2</sup>,郭瑞臣<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王海英<sup>1,2</sup>,郭瑞臣<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402015&flag=1]]></guid><cfi:id>134</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[石杉碱甲-玉米醇溶蛋白微球释放特性的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:22</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[宋韶锦<sup>1</sup>,刘华丽<sup>2</sup>,丁平田<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宋韶锦<sup>1</sup>,刘华丽<sup>2</sup>,丁平田<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401010&flag=1]]></guid><cfi:id>133</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[混合糖电解质注射液处方工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:22</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[盛照志<sup>1</sup>,刘小娟<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>盛照志<sup>1</sup>,刘小娟<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401011&flag=1]]></guid><cfi:id>132</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[挤出滚圆法制备阿托伐他汀钙速释微丸]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[刘家胜,郭玉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘家胜,郭玉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412009&flag=1]]></guid><cfi:id>131</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[替米沙坦氢氯噻嗪片的溶出度研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[郭炎]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郭炎</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412010&flag=1]]></guid><cfi:id>130</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[琥珀酸美托洛尔缓释片的制备及体外释放度考察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[宋力<sup>1</sup>,何盛江<sup>2</sup>,平其能<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宋力<sup>1</sup>,何盛江<sup>2</sup>,平其能<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411010&flag=1]]></guid><cfi:id>129</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[活血通脉软胶囊的制备及其溶出度评价]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[孔令提<sup>1</sup>,代龙<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孔令提<sup>1</sup>,代龙<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411011&flag=1]]></guid><cfi:id>128</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[单硝酸异山梨酯缓释片的制备及稳定性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[颜携国<sup>1,2</sup>,陶安进<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>颜携国<sup>1,2</sup>,陶安进<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411012&flag=1]]></guid><cfi:id>127</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[阿司匹林直接压片用复合辅料的制备及性能研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:11</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[毛政<sup>1,2</sup>,刘秀萍<sup>1</sup>,臧恒昌<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>毛政<sup>1,2</sup>,刘秀萍<sup>1</sup>,臧恒昌<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410012&flag=1]]></guid><cfi:id>126</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[胃溶型银杏叶薄膜包衣片处方和质量研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:11</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[朱晓峰,陈国喆]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>朱晓峰,陈国喆</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410013&flag=1]]></guid><cfi:id>125</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方五味子制剂中总磷量质控方法的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[胡青,于泓,孟茜,季申]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡青,于泓,孟茜,季申</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509010&flag=1]]></guid><cfi:id>124</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[瑞戈非尼固体分散体的制备及体外溶出度考察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[刘正平<sup>1,2</sup>,刘军田<sup>3</sup>,王明森<sup>1,2</sup>,张建强<sup>1,2</sup>,赵国敏<sup>1</sup>,郑德强<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘正平<sup>1,2</sup>,刘军田<sup>3</sup>,王明森<sup>1,2</sup>,张建强<sup>1,2</sup>,赵国敏<sup>1</sup>,郑德强<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509011&flag=1]]></guid><cfi:id>123</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[吡诺克辛钠滴眼液的质量分析与标准改进]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[李海霞,刘维彬,李智慧,田海燕,刘洪海]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李海霞,刘维彬,李智慧,田海燕,刘洪海</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509012&flag=1]]></guid><cfi:id>122</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[盐酸洛美沙星乳膏剂的制备与含量测定]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[李永贵<sup>1,2</sup>,王晶<sup>1,2</sup>,张锡霞<sup>1,2</sup>,刘葵葵<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李永贵<sup>1,2</sup>,王晶<sup>1,2</sup>,张锡霞<sup>1,2</sup>,刘葵葵<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508010&flag=1]]></guid><cfi:id>121</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[不同棕色玻璃安瓿对盐酸氨溴索注射液光稳定性的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[任传杰,李坤娓,黄国英,贾情情,张健]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>任传杰,李坤娓,黄国英,贾情情,张健</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508011&flag=1]]></guid><cfi:id>120</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[磺丁基醚-β-环糊精/格列本脲包合物的制备]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[刘凯,何媛]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘凯,何媛</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507011&flag=1]]></guid><cfi:id>119</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[甘川散质量标准研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[叶锦雄<sup>1</sup>,詹利之<sup>2</sup>,李睿钧<sup>1</sup>,梁志锋<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>叶锦雄<sup>1</sup>,詹利之<sup>2</sup>,李睿钧<sup>1</sup>,梁志锋<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507012&flag=1]]></guid><cfi:id>118</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射级盐酸氨溴索的制备工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[张伟锋,孟红卫]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张伟锋,孟红卫</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506010&flag=1]]></guid><cfi:id>117</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[均匀设计优化复方黄芩苷滴鼻凝胶基质处方]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[孙迎东,胡丽敏,刘明华,王玉,汪风芹]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙迎东,胡丽敏,刘明华,王玉,汪风芹</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506011&flag=1]]></guid><cfi:id>116</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[吡格列酮/二甲双胍缓释片的处方筛选及工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[张春红<sup>1</sup>,刘东<sup>2,3</sup>,龙朦朦<sup>2</sup>,韩邦兴<sup>2,3</sup>,陈乃富<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张春红<sup>1</sup>,刘东<sup>2,3</sup>,龙朦朦<sup>2</sup>,韩邦兴<sup>2,3</sup>,陈乃富<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505011&flag=1]]></guid><cfi:id>115</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[清火栀麦片的稳定性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[黄竹英,李淑如,覃仁安]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>黄竹英,李淑如,覃仁安</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505012&flag=1]]></guid><cfi:id>114</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[一种全新合成的抗抑郁药物的自微乳化载药系统(SMEDDS)理化性质和体外释药行为研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:32</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[乌兰<sup>1,2</sup>,何伟<sup>1</sup>,赵锦花<sup>2</sup>,王国成<sup>2</sup>,尹莉芳<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>乌兰<sup>1,2</sup>,何伟<sup>1</sup>,赵锦花<sup>2</sup>,王国成<sup>2</sup>,尹莉芳<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504010&flag=1]]></guid><cfi:id>113</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方布洛肾素那敏片的制备及释放度一致性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[郑忠辉,张代铭,杨爱荣,滕海峰,隋双明,潘西海]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郑忠辉,张代铭,杨爱荣,滕海峰,隋双明,潘西海</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504011&flag=1]]></guid><cfi:id>112</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[盐酸米安色林片的处方研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[李宁,张玉美,聂昌盛]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李宁,张玉美,聂昌盛</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504012&flag=1]]></guid><cfi:id>111</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[两种条件下实时测定硝苯地平片溶出度研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[林桂如<sup>1,2</sup>,熊斌<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>林桂如<sup>1,2</sup>,熊斌<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503010&flag=1]]></guid><cfi:id>110</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[芪灵扶正片质量标准研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[刘丹静<sup>1</sup>,朱庄松<sup>1</sup>,温海涛<sup>1</sup>,王志梅<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘丹静<sup>1</sup>,朱庄松<sup>1</sup>,温海涛<sup>1</sup>,王志梅<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503011&flag=1]]></guid><cfi:id>109</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[替比培南酯缓释片的制备及体外释放特性考察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[程金来,陈小伟,丁兵]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>程金来,陈小伟,丁兵</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503012&flag=1]]></guid><cfi:id>108</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[关节腔注射用氟比洛芬PLGA缓释微球的制备及体外释放特性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:06</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[刘善峰<sup>1</sup>,徐爱霞<sup>2</sup>,袁秋慧<sup>3</sup>,刘善奎<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘善峰<sup>1</sup>,徐爱霞<sup>2</sup>,袁秋慧<sup>3</sup>,刘善奎<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502008&flag=1]]></guid><cfi:id>107</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[奥美拉唑肠溶微丸胶囊的制备及质量考察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[李正元,李洪程,李风林,宋成刚]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李正元,李洪程,李风林,宋成刚</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502009&flag=1]]></guid><cfi:id>106</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[解毒止泻结肠缓释微丸释放度的方法学研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[武小赟,马静,王俊涛,夏成夫,赵小鹏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>武小赟,马静,王俊涛,夏成夫,赵小鹏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501008&flag=1]]></guid><cfi:id>105</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[正交试验优选10%氯化钾口服溶液处方及配制方法]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[张海霞,冯锐,胡丽敏,孙绍伟,马静,王玉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张海霞,冯锐,胡丽敏,孙绍伟,马静,王玉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501009&flag=1]]></guid><cfi:id>104</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The prescription process and quality standard of Yangyin Shengji Membrane]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the molding process and quality standard of the Yangyin Shengji Membrane.<b>Methods</b>  The optimum conditions about molding process of Yangyin Shengji Membrane was optimized by the single factor test and the means of the orthogonal design;The content of berberine hydrochloride was determined by HPLC and its quality standard was established.<b>Results</b>  The best molding process of the Yangyin Shengji Membrane as follow:he mass ratio of CMC-Na and PVA17-88 was 2:3,the total mass of CMC-Na and PVA17-88 in the plasma membrane was 4%,the concentration of the medicine in the plasma membrane was 2.5%.The linear range of berberine hydrochloride was 2.62～13.1 ng(<i>r</i>=0.999 3).The average recovery was 99.4%,<i>RSD</i>=1.48%(<i>n</i>=6).<b>Conclusion</b>  The screened molding process was stable and reliable.The method of measurement was simple and had good reproducibility and specificity.It can provide a basis for the quality evaluation of Yangyin Shengji Membrance.]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LUO Hui-sheng<sup>1</sup>, KOU Heng-lie<sup>2</sup>, FAN Jing<sup>1</sup> and WANG Xun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LUO Hui-sheng<sup>1</sup>, KOU Heng-lie<sup>2</sup>, FAN Jing<sup>1</sup> and WANG Xun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512010&flag=1]]></guid><cfi:id>103</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and quality control of Fluconazole Ophthalmic Gel]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare Fluconazole Ophthalmic Gel and establish its quality control standards.<b>Methods</b>  The matrix formulation was optimized by orthogonal design;HPLC was used to determine the content of fluconazole,and investigate the stimulating and stability of the preparation.<b>Results</b>  The best prescription of Fluconazole Ophthalmic Gel for quality (mass to volume ratio) were: carbomer-940 0.3%,borax 0.4% and glycerol 2%.The linear range of fluconazole was 1.0～8.0 μg (<i>r</i>=0.999 8),and the average recovery was 99.43% (<i>RSD</i>=0.75%);The prescription was stable and nonirritating.<b>Conclusion</b>  The prescription of Fluconazole Ophthalmic Gel was reasonable, and the quality was controllable.]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[MAN Yu-qing<sup>1</sup>, WEI Chuan-mei<sup>1</sup>, LIU Ming-hua<sup>1</sup>, ZUO Xiao-xin<sup>2</sup> and HU Li-min<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MAN Yu-qing<sup>1</sup>, WEI Chuan-mei<sup>1</sup>, LIU Ming-hua<sup>1</sup>, ZUO Xiao-xin<sup>2</sup> and HU Li-min<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512011&flag=1]]></guid><cfi:id>102</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation, physicochemical characterization and dissolution studies in vitro of rutin-DM-β-CD inclusion complexes]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare the rutin-DM-β-CD inclusion complex and elevate the solubilization capacity of DM-β-CD for rutin.<b>Methods</b>  Phase solubility method was used to perform a soluble experiment of rutin,drew phase solubility curves and calculated the inclusion stability constant(<i>K</i><sub>C</sub>).The characteristic of rutin-DM-β-CD inclusion complex was identified by microscopy，FT-IR and dissolution etc.<b>Results</b>  Phase solubility curves of rutin in DM-β-CD belong to typical AN.In a certain DM-β-CD concentration range,the solubility of rutin increased linearly as DM-β-CD concentration.Phase solubility profile showed that the molar ratio of rutin and DM-β-CD was 1:1. The stability constant of Rutin-DM-β-CD was 294.58 L•mol<sup>-1</sup>.<b>Conclusion</b>  Rutin was complexed in DM-β-CD,which presents new phase characteristics.It indicated that the inclusion complex was formed and the solubility of rutin was improved significantly.It was a good method to prepare rutin-DM-β-CD inclusion complex.]]></description>
<pubDate>2016/4/25 9:06:01</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[AI Fengwei, ZHANG Jiawei, QIAN Nan, FAN Chunyan and WANG Min]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>AI Fengwei, ZHANG Jiawei, QIAN Nan, FAN Chunyan and WANG Min</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511011&flag=1]]></guid><cfi:id>101</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of gypenoside self-microemulsifying drug delivery system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare gypenoside self-microemulsifying drug delivery system (SMEDDS) and evaluate its quality.<b>Methods</b>  The optimized formulation of gypenoside SMEDDS was screened by solubility,ternary phase diagrams and central composite design-response surface method with the particle size,the zeta potential and the time of self-emulsification as parameters.The physic-chemical property and dissolution characters of gypenoside SMEDDS were also determined.<b>Results</b>  The optimized formulation was composed of tween-80 (52%),glycerol(30%),ethyl oleate (26%).The average particle size after the emulsification was 51.21 nm,the zeta potential -13.7 mV,the time of self-emulsification was 30.54 s.The percent of accumulated dissolution of gypenoside in SMEDDS in vitro was 5 times of crude material at 45 min.<b>Conclusion</b>  The preparation method of gypenoside SMEDDS was feasible,which can significantly increase the dissolution of gypenoside.]]></description>
<pubDate>2016/4/25 9:06:01</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHONG Wanhua, LIU Danxia and CUI Shengmiao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHONG Wanhua, LIU Danxia and CUI Shengmiao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511012&flag=1]]></guid><cfi:id>100</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[硫酸氢氯吡格雷阿司匹林片的处方工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[李欣<sup>1,2</sup>,邢雪敏<sup>1,2</sup>,颜红<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李欣<sup>1,2</sup>,邢雪敏<sup>1,2</sup>,颜红<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510009&flag=1]]></guid><cfi:id>99</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[不同截留分子量超滤膜对羟乙基淀粉130/0.4的超滤效果比较]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[任传杰,李坤娓,黄国英,张健]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>任传杰,李坤娓,黄国英,张健</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510010&flag=1]]></guid><cfi:id>98</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Statistical analysis of rupture test and disintegration test on Vitamin E Soft Capsules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To compare the rupture test with the disintegration test on Vitamin E Soft Capsules, and find the correlations and differences between them.<b>Methods</b>  The rupture time and disintegration time of Vitamin E Soft Capsules were tested by the method in USP 39 and CHP 2015. The results were analyzed by statistical method. <b>Results</b>  There were some correlations and differences between rupture and disintegration of Vitamin E Soft Capsules. <b>Conclusion</b>  There was a significant correlation between the rupture time and production date of Vitamin E Soft Capsules (<i>P</i>＜0.01).]]></description>
<pubDate>2016/9/13 8:36:05</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Qun<sup>1,2</sup>, WANG Liying<sup>2</sup>, WANG Lei<sup>2</sup> and LIU Wanhui<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Qun<sup>1,2</sup>, WANG Liying<sup>2</sup>, WANG Lei<sup>2</sup> and LIU Wanhui<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609011&flag=1]]></guid><cfi:id>97</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The forming process and acute toxicity test of Jianpi Qushi Granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To research the forming process of Jianpi Qushi Granules and its acute toxicity after administration.<b>Methods</b>  Adjuvants were definited in forming process,the amount of dextrin and the concentration of ethanol were definited  by response surface methodology.After preparation of the samples,the acute toxicity test of Jianpi Qushi Granules in mice were carried out,and definited the acute toxicity according to the death of mice.<b>Results</b>  The preparation of Jianpi Qushi Granules was yellow,uniform size,the amounts of excipients were 17% dextrin,90% ethanol.The acute toxicity results was that: the largest dosage was 120 g·kg<sup>-1</sup> for single dose in mice.<b>Conclusion</b>  The preparation process of Jianpi Qushi Granules with 17% dextrin,90% ethanol was reliable,safe and low toxicity,and suitable for clinical application.]]></description>
<pubDate>2016/9/13 8:36:05</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[FENG Cheng<sup>1</sup>, GAO Zhihui<sup>2</sup>, WANG Ping<sup>3</sup>, TIAN He<sup>2</sup>, ZHANG Xueshun<sup>2</sup> and SUN Tiefeng<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FENG Cheng<sup>1</sup>, GAO Zhihui<sup>2</sup>, WANG Ping<sup>3</sup>, TIAN He<sup>2</sup>, ZHANG Xueshun<sup>2</sup> and SUN Tiefeng<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609012&flag=1]]></guid><cfi:id>96</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and release characteristics of Mosapride Citrate Intragastric Floating Sustained-release Pellets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare Mosapride Citrate Intragastric Floating Sustained-release Pellets and investigate the drug release mechanism in vitro.<b>Methods</b>  Extrusion-spheronization technique was introduced to prepare Mosapride Citrate Intragastric Floating Sustained-release Pellets.The amount of microcrystalline cellulose,hydroxypropyl methylcellulose,lactose and octadecanol were optimized by orthogonal design with accumulative release rate and floating time as the indexes.<b>Results</b>  The pellets with short floating time could maintain floating for more than 8 h and had a significant sustained-release profile,the drug in vitro release was in accordance with Higuchi equation.<b>Conclusion</b>  The prepared pellets showed a good floating property and sustained-release.]]></description>
<pubDate>2016/8/8 10:12:09</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[DENG Rong and DING Bing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DENG Rong and DING Bing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608010&flag=1]]></guid><cfi:id>95</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of Sodium Faropenem Orally Disintegrating Tablets by freeze-dried methods]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize the formulation of Sodium Faropenem Orally Disintegrating Tablets and detect the dissolution in vitro.<b>Methods</b>  Sodium Faropenem Orally Disintegrating Tablets was prepared by freeze-dried methods,and the formulation was optimized with the disintegrating time,friability and dissolution rate as parameters by orthogonal design.<b>Results</b>  The tablets prepared by optimum formulation were well-tasted,disintegrating fast,and had low friability.The dissolution was up to 95% within 3 min in vitro.<b>Conclusion</b>  Sodium Faropenem Orally Disintegrating Tablets can be prepared successfully using the formulation in this research.]]></description>
<pubDate>2016/7/12 14:11:37</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHU Yaoliang, CHEN Xiaowei and HAO Guizhou]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHU Yaoliang, CHEN Xiaowei and HAO Guizhou</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607010&flag=1]]></guid><cfi:id>94</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The study of prescription process certification and stability of Omeprazole Enteric Capsules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To screen the optimal prescription of Omeprazole Enteric Capsules and observe its stability.<b>Methods</b>  Omeprazole Enteric Capsules synthesised with optimizing prescription were determined according to methods of <i>China Pharmacopoeia</i>(2015 edition) for related substances,assay,acid-resistance,dissolution and the stability was investigated.<b>Results</b>  Assay,related substance,acid-resistance,dissolution and stability test of Omeprazole Enteric Capsules all met with the quality standard in <i>China Pharmacopoeia</i>(2015 edition).The capsules had good acid-resistance and dissolved fast and completely in artificial intestinal juice.<b>Conclusion</b>  This process had solved the stability of omeprazole effectively.The preparation process with good reproducibility and high accuracy was suitable for mass production.]]></description>
<pubDate>2016/7/12 0:00:00</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[RUAN Xizhe, CUI Chenghong, LI Mingjie and SUN Yiwei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>RUAN Xizhe, CUI Chenghong, LI Mingjie and SUN Yiwei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607011&flag=1]]></guid><cfi:id>93</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparative study of the stripping curve of Sanhuang Xiexin Compound Granules and single hreb formula granules in four mediums]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To compare the dissolutions of Sanhuang Xiexin Compound Granules and single herb formula granules in four common difference of dissolution medium.<b>Methods</b>  Using sirup method,water,artificial gastric juice with pH 1.2,acetate solution with pH 4.0,phosphate buffer with pH 6.8 for each 500 mL as dissolution mediums,the dissolution of two granules were determined by HPLC,and stripping curves was obtained and to compare the differences.<b>Results</b>  Artificial gastric juice with pH 1.2 was the best dissolution medium.The dissolution of Sanhuang Xiexin Compound Granules was higher than single herb formula granules.<b>Conclusion</b>  The dissolutions of two granules in four different medium were differences.The dissolution of Sanhuang Xiexin Compound Granules prepared by boiling process was more complete.In the future,the dissolution problems of single herb formula granules should be paid attention in clinical application.]]></description>
<pubDate>2016/6/21 15:47:29</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[SONG Ning, BAI Jun, LI Yang, LI Xinguang and CHEN Xin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Ning, BAI Jun, LI Yang, LI Xinguang and CHEN Xin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606011&flag=1]]></guid><cfi:id>92</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and quality evaluation of Sodium Picosulfate Film-coated Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare Sodium Picosulfate Film-coated Tablets,and carry on the quality appraisal.<b>Methods</b>  Sodium Picosulfate Film-coated Tablets were prepared by means of wet granulation.The results of content uniformity,dissolution,content and influence factors tests (high temperature,high moisture and bright light) of Sodium Picosulfate Film-coated Tablets were investigated by HPLC.<b>Results</b>  The linear range of sodium picosulfat was 4.006 4～140.224 μg•mL<sup>-1</sup>（<i>r</i>=0.999 4）.The average recovery of sodium picosulfate was 99.51%（<i>RSD</i> =1.19%）.In the influence factors test,the results showed that there was no differences in the appearance,content and dissolution.<b>Conclusion</b>  The preparation technique was reasonable and practicable,the standard was controllable.]]></description>
<pubDate>2016/6/21 15:47:29</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WU Zhenjun<sup>1,2</sup> and ZANG Hengchang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Zhenjun<sup>1,2</sup> and ZANG Hengchang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606012&flag=1]]></guid><cfi:id>91</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on dissolution of Mitiglinide Calcium Gydrate Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a dissolution determination method of Mitiglinide Calcium Hydrate Tablets and compare the self-made sample with the original preparation by stripping curves in four different dissolution media.<b>Methods</b>  The dissolution was determined with paddle method (75 rpm) in 900 mL water and detected by high performance liquid chromatography (HPLC).<b>Results</b>  There was a good linearity over the range of 2.775～33.300 μg•mL<sup>-1</sup> with a correlation coefficient <i>r</i>=0.999 9,and average recovery was 99.38%.Dissolution behaviors of self-made sample and original preparation were similar in four different dissolution media.<b>Conclusion</b>  The method was simple,accurate,reliable and the quality of Mitiglinide Calcium Hydrate Tablets can be well controlled by this method.The dissolution behaviors of two samples were very similar in vitro.]]></description>
<pubDate>2016/6/21 15:47:29</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHANG Xiaoli, LING Yiping, LUO Yaqin and XU Shaojing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xiaoli, LING Yiping, LUO Yaqin and XU Shaojing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606013&flag=1]]></guid><cfi:id>90</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the freeze dryer process of parecoxib sodium for injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the optimum technological conditions of Freeze-dryed Parecoxib Sodium for Injection.<b>Methods</b> the freeze drying process was optimized which takes the water content,related substances,content etc.as the indicators by partial factor analysis test,the following factors with three levels were considered:freeze-dryed time and drying process.<b>Results</b> The optimum technologies of freeze dryer were:vacuum was estimated to be 25 Pa,pre-freeze for 4h at -40 ℃,vacuum dryer for 15 h at 0 ℃, dryer for 10 h at 35 ℃.In the accelerated stability test for 1,2,3 months,there was no significant change on character,content etc for parecoxib sodium for injection products.<b>Conclusion</b>  The technology was feasible,the quality of infusion was fit the requirement of injection.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[SONG Yanjun<sup>1</sup>, PU Xufeng<sup>1</sup>, ZHU Peng<sup>2</sup> and LIU Xiaoshuang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Yanjun<sup>1</sup>, PU Xufeng<sup>1</sup>, ZHU Peng<sup>2</sup> and LIU Xiaoshuang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605008&flag=1]]></guid><cfi:id>89</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on in vitro release of ondansetro thermosensitive in situ gel]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare the ondansetron thermosensitive in situ gel,and  evaluate its in vitro release profiles.<b>Methods</b>  The ondansetron thermosensitive in situ gelcontrol-release system was prepared using thermosensitive in situ gel as carrier,ondansetron HPLC assay method was established,and the effects of temperatures,rotated speeds,polymer concentrations and mediums on drug release behavior were explored.<b>Results</b>  The ondansetron/poloxamer407 in situ gel was liquid under room temperature,and turned to be semisolid near the body temperature in 0.9%NaCl solution with pH6.25,drug-release regularity had Highchi square-root law model characteristic.<b>Conclusion</b>  The preparation had distinguished thermosensitive control-release characteristic,it was simple in method and easy to control in dosage,therefore it showed a promising future in the application.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WEI Pei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Pei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605009&flag=1]]></guid><cfi:id>88</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of oxaliplatin liposome and in vitro drug-release]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare oxaliplatin liposomes with high encapsulation efficiency,and to investigate the in vitro properties of them.<b>Methods</b>  Compare oxaliplatin liposomes prepared by several methods,and determine the best prescription through the single factor experiment and orthogonal experiment.In the experiment HPLC was used to determine the encapsulation efficiency,and ZetaPlus Laser Particle Size Analyzer was used to determine the particle size and zeta potential of liposomes.In addition,both HPLC method and FAAS method is used to investigate the in vitro release of the liposomes.<b>Results</b>  Compared with thin-film dispersion method and pH gradient method,liposomes prepared by reverse phase evaporation method presented higher encapsulation efficiency.The best prescription determined by formulation screening was: the ratio of drug to lipid with 1:7.5,the ratio of SPC to CH with 2:1,the ultrasonic power with 195 W and the ultrasonic time with 3 min.In vitro drug release study indicates that the accumulative releasing degree of oxaliplatin liposomes in 24 h was 25.0%,determined by HPLC,and 33.6%,determined by FAAS.<b>Conclusion</b>  Liposomes prepared by the reverse phase evaporation method were stable enough and assume high encapsulation efficiency and show the capability of sustained-releasing.]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WANG Jianzhao, LI Yanan, XIONG Yerong, SHEN Yan, TU Jiasheng and SUN Chunmeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jianzhao, LI Yanan, XIONG Yerong, SHEN Yan, TU Jiasheng and SUN Chunmeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604009&flag=1]]></guid><cfi:id>87</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The preparation of resveratrol nano-suspensions and its solidification]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare resveratrol nano-suspensions and solidify the suspensions.<b>Methods</b>  Resveratrol nano-suspensions were obtained by anti-solvent precipitation and high pressure homogenization,and the suspensions were solidified by freezing-drying process.<b>Results</b>  Anti-solvent precipitation was chosen to prepared resveratrol nano-suspensions with mean particle size of prepared nanoparticle was 120.3 nm.After solidification, the dissolution rate of resveratrol was significantly improved using in vitro experiment assay.<b>Conclusion</b>  The method used to prepare resveratrol nano-suspension was simple.It was suitable for preparing capsules or tablets after solidification.]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Kai, TONG Dajun and HE Yuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Kai, TONG Dajun and HE Yuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604010&flag=1]]></guid><cfi:id>86</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the compatibility of generic drug—Parecoxib Sodium for Injection with its packing materials]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To inspect the compatibility of generic drug—Parecoxib Sodium for Injection with its packing materials.<b>Methods</b>  By the tests of delamination and migration,positive position and inversions under the influencing factor accelerated tests to observe,determine and compare the changes of the character visible foreign matter insoluble particles,related substances,content for generic drug—Parecoxib Sodium for Injection in their study time.<b>Results</b>  No significant differences were found in the delamination and migration tests compared with its early study（<i>P</i>＞0.05）,and each index was in the acceptable safety threshold; No significant differences were found in each index for samples in positive position and inversions under the influencing factor（<i>P</i>＞0.05）,in the accelerated treatment(1,2,3 and 6 months) each index for samples of compatibility and stability were found no significant differences（<i>P</i>＞0.05）.<b>Conclusion</b>  The packing materials had good compatibily with the generic drug—Parecoxib Sodium for Injection.]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[SONG Yanjun<sup>1</sup>, PU Xufeng<sup>1</sup>, ZHU Peng<sup>2</sup> and LIU Xiaoshuang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Yanjun<sup>1</sup>, PU Xufeng<sup>1</sup>, ZHU Peng<sup>2</sup> and LIU Xiaoshuang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604011&flag=1]]></guid><cfi:id>85</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of curcumin-tetrandrine co-delivery antiviral compound recipe liposome]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare hyaluronan oligosaccharides(o-HA) modified antiviral liposome containing curcumin and tetrandrine,and study its release in vitro and stability.<b>Methods</b>  The co-deliver antiviral liposomes was prepared by film dispersion method with particle size and entrapment rate as two important indicators,using particle size analyzer to determine the particle size and ultraviolet spectrophotometric method for the determination of entrapment efficiency.<b>Results</b>  With Box- Behnken response surface optimization method, the optimal preparation (cholesterol and phospholipid ratio) was 2.5:1.The best curcumin-tetrandrine proportion was 2.8:1,and oHA was 1.80%.The particle size was 201.06 nm and entrapment efficiency was 70.94%.<b>Conclusion</b>  The preparation method showed that liposomes had good stability, uniform particle size distribution.It proved that the liposome had good in vitro release activity,good stability and had the potential use for antiviral nanocarriers.]]></description>
<pubDate>2016/4/7 9:39:54</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[SUN Jingfang<sup>1</sup>, JI Meifang<sup>2</sup>, XU Zhengxing<sup>3</sup>, LIU Zongliang<sup>1</sup>, ZHAO Feng<sup>1</sup> and CHEN Daquan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Jingfang<sup>1</sup>, JI Meifang<sup>2</sup>, XU Zhengxing<sup>3</sup>, LIU Zongliang<sup>1</sup>, ZHAO Feng<sup>1</sup> and CHEN Daquan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603011&flag=1]]></guid><cfi:id>84</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and in vitro evaluation of Ibuprofen Sustained-release Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare Ibuprofen Sustained-release Tablets and investigate the factors that influence the release rate.<b>Methods</b>  Ibuprofen Sustained-release Tablets were prepared using HPMC as hydrophilic gel framework material.The effects of dosage of HPMC and MCC in the sustained-release tablet on the release rate in vitro were studied.<b>Results</b>  The amount of HPMC and MCC could influence the release rate of ibuprofen.The release behavior in vitro of optimized Ibuprofen Sustained-release Tablets was according with Higuchi equation.<b>Conclusion</b>  Satisfied Ibuprofen Sustained-release Tablets could be obtained by adjusting the amount of excipients.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[JIANG Zhulian and CHEN Jing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Zhulian and CHEN Jing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602009&flag=1]]></guid><cfi:id>83</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effects of storage of small package decoction pieces and bulk pieces on the quality of Scutellaria baicalensis decoction pieces]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effects of on storage of small package decoction pieces and bulk pieces in TCM dispensary of hospital on the quality of <i>Scutellaria baicalensis</i> decoction pieces.<b>Methods</b>  In one-year's storage, the contents of baicalin in two different package of <i>Scutellaria baicalensis</i> decoction pieces were determined by HPLC,and to observe the changes.<b>Results</b>  In one-year's quality inspection period, the content of baicalin in small package only losed 4.31%,while bulk pieces losed 16.68%.<b>Conclusion</b>  Small package as a storage method can guarantee the quality of Scutellaria baicalensis decoction pieces.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[YUAN Xiaohang<sup>1</sup>, CHEN Xiaowei<sup>1</sup> and PENG Jiuman<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUAN Xiaohang<sup>1</sup>, CHEN Xiaowei<sup>1</sup> and PENG Jiuman<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602010&flag=1]]></guid><cfi:id>82</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of diclofenac epolamine cataplasm and its percutaneous permeability in vitro]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare diclofenac epolamine cataplasm and determine its content.To investigate the effect of penetration enhancer on the percutaneous permeability of diclofenac epolamine.<b>Methods</b>   The cataplasm was prepared with high polymer hydrophilic materials as matrix,the content was determined by HPLC.Different penetration enhancers were added in the cataplasm.The permeation of diclofenac epolamine was determined in vitro using Franz diffusion cell.<b>Results</b>  The content of cataplasm was 90%~110%.The permeation of diclofenac epolamine was related to the penetration enhancer.1% azone had the highest penetration rate,J=18.98 μg·cm<sup>-2</sup>·h<sup>-1</sup> and ER=2.38.<b>Conclusion</b>  The results showed that the cataplasm was moldability and could be easily prepared.1% azone was suitable for diclofenac epolamine cataplasm as a penetration enhancer.]]></description>
<pubDate>2016/3/22 9:29:24</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LYU YANG Gege, SUN Chunmeng, SHEN Yan, XIONG Yerong and TU Jiasheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU YANG Gege, SUN Chunmeng, SHEN Yan, XIONG Yerong and TU Jiasheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601009&flag=1]]></guid><cfi:id>81</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on quality standard for Ruxian Zengsheng Pills]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a quality control method for Ruxian Zengsheng Pills(<i>Cervi cornu degelatinatum</i>,<i>Scrophulariae radix</i>,<i>Vaccariae semen</i>,<i>Ephedrae Herba</i>,etc.).<b>Methods</b>  Scrophulariae radix was qualitatively identified by microscopical chatacteristics.<i>Vaccariae semen</i>,.<i>Ephedrae Herba</i> were qualitatively identified by TLC, and HPLC was adopted to quantitatively determine the content of ephedrine hydrochloride. The chromatographic column was Kromasil 100-5 C<sub>18</sub>（4.6 mm×250 mm,5 μm）with acetonitrile-0.1% phosphoric acid solution (10:90) as the mobile phase, the detection wavelength was 210 nm,the column temperature was 30 ℃ and the flow rate was 1.0 mL·min<sup>-1</sup>.<b>Results</b>  The TLC sports were fairly clear, and the negative control showed no interference. Ephedrine hydrochloride showed a good linear relationship within the range of 10.774～214.88 μg（<i>r</i>=0.999 7）,the average recovery was 98.42%,<i>RSD</i>=1.16% (<i>n</i>=6).<b>Conclusion</b>  The establish methods were simple and sensitive with strong specificity and good reproducibility, and can be used for effectively controlling the inherent quality of Ruxian Zengsheng Pills.]]></description>
<pubDate>2016/3/22 9:29:24</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHONG Jianqing<sup>1</sup> and HUI Jun<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHONG Jianqing<sup>1</sup> and HUI Jun<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601010&flag=1]]></guid><cfi:id>80</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and characterization of insulin-loaded microspheres with FDKP]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare and characterize Insulin-loaded FDKP microspheres.<b>Methods</b>  Insulin-loaded microspheres were prepared using FDKP as the carrier material.Box-Behnken experimental design was applied to optimize the formulation and preparation conditions to yield satisfactory drug-loading and particle size.The morphology of microspheres was recorded on a Scanning Electronics Microphotograph (SEM) and the interaction between FDKP and insulin was Investigated using the Differential Scanning Calorimeter (DSC).<b>Results</b>  The optimal formulation and preparation conditions were as follows:stirring time 2.4 h; the ratio of FDKP and insulin (W/W),15.97%;pH of suspension,4.56.The drug-loading and particle size of final product were 13.23% and 4.515 μm,respectively.The results from DSC study identified the interaction between FDKP and insulin.SEM images showed that Insulin-loaded FDKP microspheres were sphere with rose shape and porosity,surface of drug-loaded microspheres was smooth,and insulin was filled into pores of blank FDKP microspheres.<b>Conclusion</b>  The insulin-loaded FDKP microspheres manufactured using the optimal formulation and preparation conditions possess great appearance and high drug loading.]]></description>
<pubDate>2016/12/29 13:59:15</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[YANG Chen, WANG Qiyue, TU Jiasheng and SUN Chunmeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Chen, WANG Qiyue, TU Jiasheng and SUN Chunmeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612007&flag=1]]></guid><cfi:id>79</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on optimization of preparation technology for Xinnaoxin Dropping Pills by orthogonal test]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish the best forming  preparation process for Xinnaoxin dropping pills.<b>Methods</b> Indicators for the evaluation of appearance and roundness,subsidence,mean weight,weight difference and qualified rate of dropping pills.The impact of the matrix type of drop pill,ratio of base condensing agent,speed,distance,liquid and condensingtemperature,using L<sub>9</sub>(3<sup>4</sup>) orthogonal design the best molding process.<b>Results</b>  The best preparation condition was PEG-4000 and PEG-6000 with a ratio of 1:8,Powder and  matrix with a ratio of 1:2,condensing agent was dimethicone,drip system speed of 50 drops per minute,drip distance of 8 cm,liquid temperature of 80 degrees,condensing temperature is 10~12 degrees.<b>Conclusion</b>  Drop pills made by the process fits the standard of CP2015,this preparation method is suitable for the laboratory test and the industrial production．]]></description>
<pubDate>2016/12/29 13:59:15</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Yongxia<sup>1</sup> and WANG Yan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yongxia<sup>1</sup> and WANG Yan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612008&flag=1]]></guid><cfi:id>78</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research of extraction and inclusion technology of volatile in Shouwuyizhi Capsules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize the process of volatile oil extraction and β-cyclodextrin（β-CD）inclusion from Fructus Alpiniae Oxyphyllae and Rhizoma Chanxiong in Shouwuyizhi Capsules.<b>Methods</b>  Amount of volatile oil was adopted as observation index,and extraction process of volatile oil was optimized by orthogonal test.Inclusion rate of volatile oil and yield of inclusion compound were used as comprehensive assessment parameters to optimize β-CD inclusion technology and perform inclution validation.<b>Results</b>  The optimum extraction process of volatile oil were:water volume of 8 time, extraction time 5 hours;The optimum inclusion technology of volatile oil were:ratio of volatile oil to β-CD was 1:9,inclusion temperature 35 ℃,inclusion time 2 hours.<b>Conclusion</b>  The optimized extraction technology had a high rate of oil yield.The optimized inclusion technology was stable,had a high rate of inclusion.The operation method was simple,it can be used as the preparation of volatile oil extraction and inclusion process.]]></description>
<pubDate>2016/11/9 9:59:02</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[DING Xiaoyan, ZHANG Xinjun and ZHAO Bonian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Xiaoyan, ZHANG Xinjun and ZHAO Bonian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611008&flag=1]]></guid><cfi:id>77</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of sodium alginate in Metformin Hydrochloride Sustained-release Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare metformin hydrochloride sustained-release tablets with sodium alginate as sustained-release materials.<b>Methods</b>  To compare the dissolution profile and stability between domestic and the brand drug with sodium alginate as sustained-release material in Metformin Hydrochloride Sustained-release Tablets.<b>Results</b>  Similarity factors (<i>f<sub>2</sub></i>) of several critical pH dissolution medium between domestic and the brand drug was more than 70,and the related substances of domestic are no significant increase,the average tablet weight of domestic was 850 mg,while the brand drug was 1 000 mg.<b>Conclusion</b>  With sodium alginate as sustained-release materials,Metformin Hydrochloride Sustained-release Tablets had the same dissolution profile as the brand drug.The formulation and process of Metformin Hydrochloride Sustained-release Tablets with sodium alginate as sustained-release materials were reasonable and practicable,its process was stable and the quality was controlled.]]></description>
<pubDate>2016/11/9 9:59:02</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WANG Fuzhou, WANG Zhonghua and HAO Guanhua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Fuzhou, WANG Zhonghua and HAO Guanhua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611009&flag=1]]></guid><cfi:id>76</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The stability test of Yimianda Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  According to Yimianda Tablets’ quality standards,to study the stability of Yimianda Tablets.<b>Methods</b>  By the acceleration testing and long-term test,integrated survey Yimianda Tablets’ identification,inspection,traits,disintegration time limit,the difference of weight，microbial limit the content of fructus schisandrae alcohol armour.<b>Results</b>  After 6 months of the accelerated test,the results of test item for Yimianda Tablets didn’t have obvious change.But after 18 months of the long-term test,there were 2 batch test samples’ number of bacteria didn’t conform to the standard.<b>Conclusion</b>  According to test data,tentative the term of validity of Yimianda tablets was 12 months.]]></description>
<pubDate>2016/10/12 14:45:15</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WANG Tao<sup>1</sup>, ZAHNG Yuhua<sup>2</sup>, HU Weidong<sup>1</sup>, ZHOU Yuanlong<sup>2</sup>, WANG Pei<sup>2</sup> and LI Yufang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Tao<sup>1</sup>, ZAHNG Yuhua<sup>2</sup>, HU Weidong<sup>1</sup>, ZHOU Yuanlong<sup>2</sup>, WANG Pei<sup>2</sup> and LI Yufang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610009&flag=1]]></guid><cfi:id>75</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and in vitro evaluation of Nitrendipine Solid Dispersion Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610010&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare Nitrendipine Solid Dispersion Tablets.<b>Methods</b>  nitrendipine solid dispersion was first prepared by solvent method or fusion method and then mixed with other accessories to prepare Nitrendipine Dispersible Tablets.<b>Results</b>  The dissolution of Nitrendipine Dispersible Tablets prepared with solid dispersion was improved.The dispersible tablets prepared with PEG showed faster dissolution than those prepared with PVP.<b>Conclusion</b>  Dispersible tablets prepared using solid dispersion technology can improve the dissolution of insoluble drug.]]></description>
<pubDate>2016/10/12 14:45:15</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WU Lin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Lin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610010&flag=1]]></guid><cfi:id>74</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and evaluation of bacteriostatic agent application in domestic eye drops]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[To promote the quality improvement of the domestic eye drops,and provide suggestions for future research and development,analysis and evaluation of the current situation of bacteriostatic agent application indomestic eye drops were conducted based on the related laboratory results of special evaluation for 4 consecutive years,in combination with the finding of related research literature.The analysis focused on the application background,pharmacopoeia standard of different countries,problem discussion and so on.The application of antibacterial agents in domestic eye drops has drawn more and more attention.However,the testing standards were not unified,and these should be addressed in the future.Meanwhile,it is suggested that enterprises consider single dose packaging during the development of new product to reduce the dependence of bacteriostatic agents.]]></description>
<pubDate>2017/9/21 9:45:57</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[XIAO Huang, DAI Hui, YANG Meiqin, WANG Sijin, HU Changqin and MA Shihong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIAO Huang, DAI Hui, YANG Meiqin, WANG Sijin, HU Changqin and MA Shihong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709007&flag=1]]></guid><cfi:id>73</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of in vitro dissolution of Xingnao Zaizao Pills big honey pill and water honey pill]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a method for the dissolution of Xingnao Zaizao Pills,and compare the difference of in vitro dissolution of two different dosage forms of the big honey pills and the water honey pills with the total flavonoids.<b>Methods</b>  the second method of paddle method of dissolution determination method was adopted, the cumulative dissolution rates of the large honey pill and water honey pills in four dissolution media were determined.The contents of total flavonoids in the two formulations of Xingnao Zaizao Pills were determined by UV-Vis spectrophotometry.The dissolution behavior of the two preparations was compared.<b>Results</b>  The cumulative dissolution rates of water honey pills in four dissolution media were 51.57%,71.97%,24.73% and 50.78%,respectively.The cumulative dissolution rates of large honey pill in four dissolution media were 41.94%,69.82%,16.10% and 48.52%,respectively.From the difference factor and the similarity factor analysis, the dissolution curves of the same components in the two preparations had no similarity.<b>Conclusion</b>  In this paper,a method for the determination of the dissolution rate of the Xingnao Zaizao Pills was established.The cumulative dissolution rate of water honey pills in two kinds of preparations was fast.The results indicated that in vitro dissolution,the water honey pill was conducive to the body's full absorption of drugs,and had high bioavailability.]]></description>
<pubDate>2017/9/21 9:45:57</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LI Xinguang, LI Yang, LIU Jishuang, LI Na, XU Ben, ZHANG Yarong and CHEN Xin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xinguang, LI Yang, LIU Jishuang, LI Na, XU Ben, ZHANG Yarong and CHEN Xin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709008&flag=1]]></guid><cfi:id>72</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation technology research of licoflavone phospholipid complex]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize the preparation technology of licoflavone phospholipid complex and improve physico-chemical property.<b>Methods</b>  With the compound rate of licoflavone and phospholipid as index,the preparation technology of complex was optimized by orthogonal design method on the basis of the effects of complex solvent,temperature,time,initiate concentration and ratio of feeding were investigated on compound rate by single factor method.The apparent solubility of phospholipid complex was examined.<b>Results</b>  The optimized conditions for licoflavone phospholipid complex were as follows:licoflavone and phospholipids (l:1.5,weight ratio) were complexed in ethanol.30 ℃ for 1.5 h with the final concentration of total flavonoids being 5 g·L<sup>-1</sup>.The result showed that the compound rate was over 96% with the optimized preparation technology.The solubility of compound of licoflavone phospholipid in water was effectively enhanced.<b>Conclusion</b>  The preparation was stable,phospholipid can effectively enhance the solubility of licoflavone.]]></description>
<pubDate>2017/8/30 13:48:10</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHANG Wenhua<sup>1</sup>, ZHANG Fang<sup>2</sup>, WANG Hanqing<sup>3,4</sup>, QUAN Hongfeng<sup>3,4</sup> and ZHANG Xia<sup>3,4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Wenhua<sup>1</sup>, ZHANG Fang<sup>2</sup>, WANG Hanqing<sup>3,4</sup>, QUAN Hongfeng<sup>3,4</sup> and ZHANG Xia<sup>3,4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708007&flag=1]]></guid><cfi:id>71</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optimization of microwave-assisted extraction processes of gentiopicroside from <i>Radix Gentiana Macrophylla</i> using response surface methodology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To determine the optimum process of microwave-assisted extraction of gentiopicroside from <i>Radix Gentiana Macrophylla</i>.<b>Methods</b>  Ethanol concentration,extraction time and the ratio of solvent volum to matermial weight were selected as independent variables of response surfacd methodology to study the effects of various factors and their interactions on extraction of gentiopicroside from <i>Radix Gentiana Macrophylla</i>.The extraction regression equation for gentiopicroside was obtained by simulation and the optimum extraction conditions of gentiopicroside were determined.<b>Results</b>  The optimum parameters were as follows:ethanol concentration 74%,the ratio of solvent volum to matermial weight 27 mL·g<sup>-1</sup> and extraction time 4.7 min.The extraction rate of gentiopicroside from <i>Radix Gentiana Macrophylla</i> was 6.33% under the optimized conditions.<b>Conclusion</b>  The optimized extraction process is stable, reasonable and highly predictive.]]></description>
<pubDate>2017/7/21 15:57:14</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHANG Wenhua<sup>1</sup>, XU Lisheng<sup>2</sup> and ZHANG Xia<sup>2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Wenhua<sup>1</sup>, XU Lisheng<sup>2</sup> and ZHANG Xia<sup>2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707008&flag=1]]></guid><cfi:id>70</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmacokinetic research of oral Mildronate Capsule in healthy Chinese subjects]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the pharmacokinetics of mildronate capsules in healthy subjects in a single and multiple dose.<b>Methods</b>  Using multi-dose of single-sequence for drug design,12 healthy subjects were respectively numbered according to the weight from heavy to light order number,all the female volunteers were behind the male volunteers.All the volunteers were given the low doses of 250 mg (250 mg/pill×1) medicine;After cleaning period all the volunteers were given the high doses of 1 000 mg (500 mg/pill×2) medicine;Again after cleaning period all the volunteers were given the dose 500 mg (500 mg/pill×1) medicine,and then all the volunteers were given the middle-dose of this medicine(oral drug 6 days in a row,oral this medicine twice a day from the first day to the fifth day,oral the medicine once time in the morning of the sixth day,Every time the dose is 500 mg).<b>Results</b>  The pharmacokinetic characteristics of mildronate were nolinear pharmacokinrtics in human body.The t1/2 was prolonged with increasing does,the result of multiple dose indicated the occurrence of accumulation in the multidoses.<b>Conclusion</b>  The method developed in this study was suitable for the pharmacokinetic study of mildronate.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[YU Liyan, SUN Rongmei, RAN Guimei and XIANG Bingren]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YU Liyan, SUN Rongmei, RAN Guimei and XIANG Bingren</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706008&flag=1]]></guid><cfi:id>69</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Evaluation on the quality of processed <i>Magnolia officinalis</i> from Shandong Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the quality of processed <i>Magnolia officinalis</i> from Shandong Province.<b>Methods</b> HPLC method was used for the determination of magnolol and honokiol.Inspecting items of microscopic identification,TLC,water,total ash,acid-insoluble ash,and sulfur dioxide residues were developed.<b>Results</b>  There was a obvious difference between the content of magnolol and honokiol in thirty-five batches of samples,with the total content between 1.0%~6.4%,which showed significant quality difference of <i>Magnolia officinalis</i> in the market circulation.<b>Conclusion</b>  This study provided the experimental basis for the quality evaluation of processed <i>Magnolia officinalis</i> from Shandong Province.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZANG Yuanfang and LIN Yongqiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZANG Yuanfang and LIN Yongqiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706009&flag=1]]></guid><cfi:id>68</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effect of actuator dimensions and add-on devices for inhalation on the deposition of metered dose inhaler in vitro]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate effects of actuator dimensions（the aperture and the hole length）and add-on devices for inhalation on the deposition of metered dose inhaler in vitro.<b>Methods</b>  Self-made metered dose inhalers (MDI) of fluticasone propionate were selected as the model drug,and then assembled different dimensions of actuators.The deposition of metered dose inhaler in vitro was determined by Andersen cascade impactor (ACI).Fluticasone propionate aerosols were loaded on specific actuator.Thus,a comparative study was conducted in vitro deposition with and without add-on devices.<b>Results</b>  When the value of aperture was fixed,increasing the hole length could reduce the amount of residue in the actuator and increase the drug deposited in the L type connection tube.Moreover,the deposition of fine particle distribution decreased slightly.Likewise,when the value of the hole length was fixed,increasing the diameter could reduce the amount of residue in the actuator and increase the amount of drug deposited in the L type connection tube.At the same time,the value of fine particle distribution was decreased.According to the experiment results, the characteristic of suspension aerosol and the actual use,actuator of 0.42 mm aperture and 0.70 mm hole length can be chosen as the priority.Add-on device can hold back the big particle,thus the drug deposition in the L type connection tube was greatly reduced,and the value of fine particle distribution is increased.<b>Conclusion</b>  Actuator dimensions can affect the deposition of metered dose inhaler in vitro.According to the specific characteristics of aerosol products(solution or suspension,raw material particle size),actuators can be chosen in the drug research.The use of add-on devices can improve the drug utilization of aerosol,and it was recommend that patients use the add-on devices for inhalation.]]></description>
<pubDate>2017/5/23 16:01:09</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[CHEN Baolei, ZHU Jun, LU Jiatong and JIN Jian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Baolei, ZHU Jun, LU Jiatong and JIN Jian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705007&flag=1]]></guid><cfi:id>67</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on qualitative and quantitative analysis for Jiangu pills]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish qualitative and quantitative method of Jiangu Pills.<b>Methods</b>  <i>Angelica</i>,<i>Ligusticum wallichii</i>,<i>Carthamus tinctorius</i> L. were identified by TLC.The content of paeoniflorin in <i>Paeonia lactiflora</i> Pall.The analysis was performed on a C<sub>18</sub> column  with the mobile phase of Acetonitrile-0.1% Phosphoric acid solution (15:85) at a  flow rate  of 1.0 mL·min<sup>-1</sup>,the detection wavelength was 230 nm.<b>Results</b>  <i>Angelica</i>,<i>Ligusticum wallichii</i>,<i>Carthamus tinctorius</i> L. can be identified by TLC.Paeoniflorin showed a good linear relationship(<i>r</i>=0.999 9) in the range of 0.108 8～2.176 0 μg,the average recovery was 99.73%(<i>n</i>=9).<b>Conclusion</b>  This method was simple,accurate,can be used to control the quality of Jiangu Pills.]]></description>
<pubDate>2017/5/23 16:01:09</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZOU Ailing<sup>1</sup> and SUN Juan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZOU Ailing<sup>1</sup> and SUN Juan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705008&flag=1]]></guid><cfi:id>66</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of hollow gold nanoparticles by silver template method and its quality evaluation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare and characterize a hollow gold nanoparticles for loading drugs.<b>Methods</b> Preparing silver nanoparticles as templates,chloroauric acid was reacted with silver nanoparticles to produce gold shells by template-engaged replacement reactions.Then gold wrapped on the surface of silver nanoparticles,and finally formed a kind of hollow structure.The study on the preparation of hollow gold nanoparticles was carried out by single factor investigation.The structure of hollow gold nanoparticles was observed by transmission electron microscopy,and the absorption by UV scanning was investigated.Photothermal transformation of the carrier was researched by in vitro photothermal transformation experiment.And MTT assay was used to investigate the cytotoxicity of the vector.<b>Results</b>  The hollow gold nanoparticles had a particle size of 35~55 nm with a shell thickness of 4~6 nm.The maximum absorption wavelength was 750~800 nm.And the preparation had good photothermal conversion ability.Cytotoxicity study in vitro indicated that the hollow gold nanoparticles did not cause significant toxicities on the HDF cells.<b>Conclusion</b>  The optimized hollow gold nanoparticles had better hollow structure,good photothermal conversion ability and smaller cototoxicity.]]></description>
<pubDate>2017/5/2 14:32:09</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[YOU Chen, LI Lin, YANG Wenqian, SHEN Yan and TU Jiasheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YOU Chen, LI Lin, YANG Wenqian, SHEN Yan and TU Jiasheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704007&flag=1]]></guid><cfi:id>65</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effect of compatible stability and safety of Omeprazole Sodium for Injection with Coenzyme Q10 Sodium Chloride Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the compatible stability and safety of Omeprazole Sodium for Injection with Coenzyme Q10 Sodium Chloride Injection,provide basis for clinical application.<b>Methods</b>  Omeprazole Sodium for Injection was dissolved in Coenzyme Q10 Sodium Chloride Injection and Sodium Chloride Injection respectively according to the clinical dose 0.4 mg·mL<sup>-1</sup>,stay for 4 h, HPLC method was used to determine the content of main component and related substances,investigate the stability of the drug.Allergy test,in vitro hemolysis test,vascular irritation test studies were performed to investigate the safety of the drug.<b>Results</b>  The HPLC assay showed no significant difference in the content of the principal component and the related substances.Futhermore,The allergy test and vascular stimulation test are all showed negative results of two test articles at concentration of 0.4 mg·mL<sup>-1</sup> solution.In vitro hemolysis test showed negative results of test articles both in concentration of 0.6 mg·mL<sup>-1</sup> and 0.24 mg·mL<sup>-1</sup>.<b>Conclusion</b>  Coenzyme Q10 Sodium Chloride Injection had no significant effect on the stability and safety of Omeprazole Sodium for Injection compared to Sodium Chloride Injection.]]></description>
<pubDate>2017/5/2 14:32:09</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WEI Xia, LIU Na, XIE Qiangsheng, GENG Xue and ZHU Qingfen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Xia, LIU Na, XIE Qiangsheng, GENG Xue and ZHU Qingfen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704008&flag=1]]></guid><cfi:id>64</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study of reentrainment of cascade impactor used for determination of aerodynamic particle size distribution of dry powder for inhalation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study particle bounce and reentrainment of cascade impactor used for determination of aerodynamic particle size distributions (APSDs) of dry powder for inhalation.And give an investigation about different coating material.<b>Methods</b>  Following the guidance of USP,the samples were made by using cascade impactor,where collection cups/plates were either left uncoated or coated with Glycerin or Silicone oil,at flow rates ranging from 30~90L·min<sup>-1</sup>.Different does were delivered.<b>Results</b>  Coating collection surfaces had reduced the deposition on filter paper.And silicone oil coating had an unapparent impact on mass median aerodynamic diameter (MMAD),and the APSDs were nearly regardless of does.<b>Conclusion</b>  This study showed that collection surface coating can eliminate particle bounce and re-entrainment.For glycopyrronium bromide dry powder for inhalation determined by next generation impactor (NGI),the use of Silicone oil as cup coating,preferably with Glycerin, reduced particle bounce.]]></description>
<pubDate>2017/4/17 14:20:00</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LU Jiatong and JIN Jian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LU Jiatong and JIN Jian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703008&flag=1]]></guid><cfi:id>63</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparative study on the dissolution curves of Febuxostat Tablet]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To confirm the measurement conditions of dissolution curves which have distinguished capability and to investigate the consistency of the in vitro dissolution behavior of self-made tablets and the original tablets.<b>Methods</b>  To compare the dissolution curves of self-made tablets and the original tablets in different conditions. The chosen dissolving conditions are pH 6.0 buffer solution(FDA announced conditions), 50 rpm and 75 rpm, 900 mL dissolution solution; 0.2%, 0.3% and 0.5% SDS in water, 50 rpm, 900 mL dissolution solution; pH 1.2, pH 4.5 and pH 6.8 buffer solution, 50 rpm, 900 mL dissolution solution.<b>Results</b>  The dissolution behavior of the original sample under 0.3% SDS condition was more ideal.The f2 value of the self-made sample and the original sample was greater than 50 or in 15 min the cumulative dissolution was more than 85%.<b>Conclusion</b>  Results showed that the dissolution behavior of the self-made samples was basically the same as that of the original sample. To provide experimental basis for generic drugs quality consistency evaluation.]]></description>
<pubDate>2017/3/28 14:39:38</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[MA Wenxia<sup>1</sup>, TANG Chunyan<sup>2</sup>, LIU Qiumin<sup>1</sup> and FAN Zhongshu<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Wenxia<sup>1</sup>, TANG Chunyan<sup>2</sup>, LIU Qiumin<sup>1</sup> and FAN Zhongshu<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702007&flag=1]]></guid><cfi:id>62</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and quality control of Compound Qin E Plastics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the preparation and quality control method for Compound Qin E Plastics.<b>Methods</b>  Compound Qin E Plastics was prepared with polyvinyl alcohol-124 as the membrane material,a quality control method was established,and determination methods of the main components was developed and validated.<b>Results</b>  The preparation process was reasonable,the method of quality control was feasible,the product had stable quality,and the drugs did not cause skin irritation in rabbits.<b>Conclusion</b>  Compound Qin E Plastics was in line with the standards and requirements of plastics,and available for clinical application.]]></description>
<pubDate>2017/3/28 14:39:38</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[SONG Lengmei, JIANG Hong, SONG Zheng and LI Baoyuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Lengmei, JIANG Hong, SONG Zheng and LI Baoyuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702008&flag=1]]></guid><cfi:id>61</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on quality standard for Heqi Jieyu granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish the quality control standard for Heqi Jieyu granules.<b>Methods</b>  TLC was used to Angelica sinensis,Forsythia suspensa and Glycyrrhiza uralensis in Heqi Jieyu granules.HPLC was used to determine the content of phillyrin.<b>Results</b>  Angelica sinensis,Forsythia suspena and Glycyrrhiza uralensis were well identiified by TLC,and the negative control had no interference.Phillyrin showed a good linear relationship within 0.39~3.19 mg(<i>r</i>=0.999 8).The average recovery rate was 99.8%,with a relative standard deviation of 1.15%.<b>Conclusion</b>  The method is simple,reliable and accurate,and can be applied as the quality control]]></description>
<pubDate>2017/2/27 15:13:05</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[JIANG Li<sup>1</sup>, LI Ting<sup>2</sup>, ZHAO Jinxiang<sup>1</sup> and WANG Shumin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Li<sup>1</sup>, LI Ting<sup>2</sup>, ZHAO Jinxiang<sup>1</sup> and WANG Shumin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701009&flag=1]]></guid><cfi:id>60</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmacokinetics study of a new entecavir tablet formulation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish and validate the LC-MS/MS bioanalytical method for the determination of entecavir in rat plasma and pharmacokinetics evaluation of a new formulation of entecavir.<b>Methods</b>  A LC-MS-MS bioanalytical method for the determination of entecavir in rat plasma was established and validated.The pharmacokinetics of the new entecavir formulation and its brand drug Boluding Tablets were then tested under normal food feeding by using the newly validated bioanalytical method.<b>Results</b>  The bioanalytical method for the determination of entecavir in rat plasma was established and method validation met the validation requirements.The pharmacokinetics study showed that the AUCs of the new entecavir formulation and brand drug Boluding Tablets were determined to be 672.5±65.7 and 461.3±10.9 ng·h·mL<sup>-1</sup>,respectively.The half-lifes (t<sub>1/2</sub>) of the new entecavir and its brand drug Boluding Tablets were found to be 11.06±3.21 and 6.66±0.92 h,respectively.<b>Conclusion</b>  The test results showed that the new entecavir tablets were obviously better than that of the original drug Boluding Tablets under normal food feeding.The AUC of the new entecavir formulation was increased by 46.1% and its half-life (t<sub>1/2</sub>) was extended by 67.1% compared with the Boluding Tablets.In comparison with Boluding Tablets,the normal food feeding did not decrease the oral bioavailability of the new entecavir tablets.Therefore,the newly developed entecavir formulation could improve its bioavailability as well as effectively overcome the food effect of the Boluding Tablets.]]></description>
<pubDate>2018/1/4 15:58:19</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LI Nan, JIANG Xiaoyan, YANG Min, XU Hongya and ZHAO Zhongxi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Nan, JIANG Xiaoyan, YANG Min, XU Hongya and ZHAO Zhongxi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712008&flag=1]]></guid><cfi:id>59</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optimization of extraction process for astragaloside in Feiwei Granules by supercritical CO<sub>2</sub> extraction technique]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize extraction technique of astragaloside in Feiwei Granules by supercritical CO<sub>2</sub> extraction technique.<b>Methods</b>  In this experiment the supercritical CO<sub>2</sub> extraction method was used to extract Feiwei Granules with crushing grain size,extraction time  cosolvent concentration, solvent flow rate,Astragaloside yield as inspection index.<b>Results</b>  The experimental results showed the optimal conditions of supercritical CO<sub>2</sub> extraction method:the size was 40 mesh,extraction time was 1.5 h,cosolvent concentration was 95% alcohol, rate was10 mL•min<sup>-1</sup>.<b>Conclusion</b>  This extraction process was feasible and provided scientific basis for extraction method of Feiwei Granules.]]></description>
<pubDate>2018/1/4 15:58:19</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[SONG Zhenmin<sup>1</sup>, LI Jing<sup>2</sup>, XU Tiantian<sup>1</sup>, GUO Ying<sup>1</sup> and WANG Juan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Zhenmin<sup>1</sup>, LI Jing<sup>2</sup>, XU Tiantian<sup>1</sup>, GUO Ying<sup>1</sup> and WANG Juan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712009&flag=1]]></guid><cfi:id>58</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of self-control method in consistency evaluation of dissolution curve of Aspirin Enteric-coated Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a  self-control method for the determination of dissolution curves of Aspirin Enteric-coated Tablets and explore the method in the quality of generic drug evaluation.To compare the dissolution curves of aspirin enteric-coated tablets from 3 pharmaceutical manufactures in 3 dissolution mediums and discuss on the quality consistency between reference listed drug（RLD） and generic drug.<b>Methods</b>  Basket method was adopted at 100 rpm,dissolution mediums was hydrochloride acid solution（pH 1.0）and phosphate buffer（pH 6.8 and pH 7.4）,the dissolution profiles were determined with self-control method and HPLC.<b>Results</b>  The linear range of aspirin was 10～120 μg·mL<sup>-1</sup> and the correlation coefficient was 1.000.The recoveries were 100.7%～101.8%，with <i>RSD</i>s of 0.71%～0.94% in 3 dissolution mediums.The results of dissolution test are basically the same as those of HPLC.In the pH 1.0 hydrochloric acid solution,the dissolution of aspirin enteric-coated tablets from three manufacturers was basically the same.In the other two dissolution media,the dissolution profiles of the generic drug were not similar to the RLD.<b>Conclusion</b>  The self-control method was simple,accurate and feasible.It can be used as a method for the determination of dissolution in the quality consistency evaluation of generic drug.]]></description>
<pubDate>2017/12/7 15:02:26</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[NIE Yanjun, ZHENG Jing, CHEN Zhen and XIE Yuanchao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>NIE Yanjun, ZHENG Jing, CHEN Zhen and XIE Yuanchao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711009&flag=1]]></guid><cfi:id>57</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Dissolution determination of Candesartan Cilexetil andAmlodipine Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a dissolution method of candesartan cilexetil andamlodipine in Candesartan Cilexetil and Amlodipine Tablets.<b>Methods</b>  According to the second dissolution method(paddle method)stated in the appendix of <i>Chinese Pharmacopeia</i>(2010 edition),dissolution medium of candesartancilexetil was purified water containing 1% polysorbate 20 and the rotating speed was 50 rpm,after 45 min, the dissolution solution was taken; Dissolution medium of amlodipine was 0.01mol·L<sup>-1</sup> hydrochloric acid solution and the rotating speed was 50 rpm,after 30 min,the dissolution solution was taken.C<sub>18</sub> column was used, mobile phase was that methanol- acetonitrile-20 mmol·L<sup>-1</sup> decane sulfonate solution [containing 0.04 mol·L<sup>-1</sup> KH<sub>2</sub>PO<sub>4</sub> (phosphate tune pH 3.5)] (600:100:300), the detection wavelength was 238 nm and the flow rate was 1.0 mL·min<sup>-1</sup>.<b>Results</b>  The linear range of candesartan cilexetil was 0.562 ~ 8.992 ug·mL<sup>-1</sup>(<i>r</i>=0.9998) and amlodipine was 0.292 ~4.672 ug·mL<sup>-1</sup> (<i>r</i>=0.9995),the average recovery of candesartan cilexetil and amlodipine besylate were 101.0%±0.8% and 100.5%±0.9%,respectively.The dissolution of candesartan cilexetil was above 75% and amlodipine was above 80%.<b>Conclusion</b>  The method was convenient and sensitive in the dissolution determination of Candesartan Cilexetil and Amlodipine Tablets.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[XU Bin<sup>1</sup>, MAO Ke<sup>1</sup>, WU Xiaogang<sup>1,2</sup> and CHEN Ning<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Bin<sup>1</sup>, MAO Ke<sup>1</sup>, WU Xiaogang<sup>1,2</sup> and CHEN Ning<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710008&flag=1]]></guid><cfi:id>56</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and quality evaluation of paeonolum gelatin microspheres]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the pharmaceutical properties of paeonolum loaded gelatin microspheres.<b>Methods</b>  Paeonol loaded gelatin microspheres were prepared by crosslinking solidification method using paeonol as core materialand gelatin as wall material.The preparation technology was optimized by orthogonal test and in vitro drug release properties of the microspheres were investigated.<b>Results</b>  The main factors that influence the encapsulation efficiency of gelatin microspheres were gelatin concentration and stirring speed.The microspheres had an average size of 100 μm,and drug loading and encapsulation efficiency of microspheres were 8.49% and 86.4%,respectively.<b>Conclusion</b>  The optimized process can be used to prepare paeonol loaded gelatin microspheres,which can provide reference for the development of sustained release drug delivery system.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[XU Aixia<sup>1</sup>, YANG Chuanhong<sup>1</sup> and WANG Hailong<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Aixia<sup>1</sup>, YANG Chuanhong<sup>1</sup> and WANG Hailong<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710009&flag=1]]></guid><cfi:id>55</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and prescription optimization of Captopril Pulse Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare the pulsatile release tablets of Captopril.<b>Methods</b>  The core of tablet was manufactured by wet-granulation squashing squashing mathod and useing melting method to prepare waxy coated. The evaluation parameter was lag time. Experiments were done on the central composite design. The possibly optimal formulation was predicted by response surface method. The lag time of the tablets prepared under the optimum condition was compared with the predicted.<b>Results</b>  Optimized to the best prescription,PVPP was 10%, PEG6000 was 34.32%, hardness was 4.The lag time in vitro of the tablets prepared under the optimum conditions was about 250 minutes and the pulsatile release tablets was able to float in 30 min and keep floating.<b>Conclusion</b>  Central composite design-response surface methodology was successful in optimizing the preparation of tablets with accurate prediction and to prepare the pulsatile release tablets have good control of release.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LI Xin, ZHANG Qi, ZHAO Yingying, DENG Leilei and TANG Mingrui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xin, ZHANG Qi, ZHAO Yingying, DENG Leilei and TANG Mingrui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809007&flag=1]]></guid><cfi:id>54</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on preparation process of Sechang Capsules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the preparation process of Sechang Capsules.<b>Methods</b>  Sechang Capsules were prepared by pulverization and sterilization test, water decoction extraction test, water decoction concentration test, particle preparation process test, capsule filling test.<b>Results</b>  The average powder extraction rate of Radix Aucklandiae in this test was 97.7%;Continuous operation of heating and cultivating for 3 times by low-temperature intermittent sterilization method;The amount of water added was selected as “10+8” times; 4% PVP anhydrous ethanol solution was used as adhesive,and the drying time at (45 ± 5) ℃ was 1.5 h.<b>Conclusion</b>  The process was reasonable,feasible,and was suitable for the production of Sechang Capsules.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Qun<sup>1</sup>, REN Qiming<sup>2</sup> and LIAN Chuanbao<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Qun<sup>1</sup>, REN Qiming<sup>2</sup> and LIAN Chuanbao<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809008&flag=1]]></guid><cfi:id>53</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optimization of the preparation technology of the raphasatin from radish sprouts by response surface methodology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize the preparation technology of raphasatin.<b>Methods</b>  The enzymatic reaction condition was determined and optimized by response surface method (RSM).<b>Results</b>  Through the process optimization experiment, the obtained optimal conditions of enzymetic hydrolysis were as follows:the pH value of buffer solution was 5.79, the enzymetic hydrolysis time was 49 min, the material liquid ratio was 33.12% and the content of Vc was 6.9 mmol·L<sup>-1</sup>.Under the optimal conditions, the yield and recovery of raphasatin during enzymetic hydrolysis were 7.39 mg·g<sup>-1</sup> and 60.21%.Validation test in enzymatic hydrolysis yield was 58.68%.<b>Conclusion</b>  The experimental results show that this method was available, its comprehensive utilization of raphasatin and new product research and development was of great significance.]]></description>
<pubDate>2018/8/27 10:55:10</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WANG Zhaoling<sup>1</sup>, FENG Shangcai<sup>1</sup> and KUANG Penqun<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Zhaoling<sup>1</sup>, FENG Shangcai<sup>1</sup> and KUANG Penqun<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808008&flag=1]]></guid><cfi:id>52</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on multiplying and enlarging technology of Atorvastatin Calcium Tablets production batch]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the mass changes of Atorvastatin Calcium Tablets in production batches and compare them with the release behavior of commercial preparations.<b>Methods</b>  The quality of soft materials,granules and tablets prepared in three batches of production batch was compared,and the quality changes of each pot were observed,The dissolution curves of homemade products and reference preparations of different cooking times were determined by UV.<b>Results</b>  The results showed that the dissolution curves of homemade products and reference products were similar.<b>Conclusion</b>  With the increase of batch volume,the quality of each pot changed slightly.According to this trend,the batch can not be enlarged without limit,but the batch volume was increased from 200 000 to 600 000, and the process was stable and feasible, which was consistent with the release behavior of the referenced preparation.]]></description>
<pubDate>2018/8/27 10:55:10</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WANG Hai<sup>1</sup>, LI Yongliang<sup>1</sup> and XU  Weina<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Hai<sup>1</sup>, LI Yongliang<sup>1</sup> and XU  Weina<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808009&flag=1]]></guid><cfi:id>51</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of Nifedipine Osmotic Pump Tablets with povidone and copovidone as carrier]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the preparation of Nifedipine Osmotic Pump Tablets with povidone as carrier.<b>Methods</b>  The similarity factor between the release behavior of the osmotic tablets and the target drug release curve was used as the evaluation index to optimize the prescription by single factor screening and central composite design-response surface methodology.<b>Results and Conclusion</b>  The practical formulation and manufacturing processing of Nefidipine Osmotic Pump Tablets were obtained, which was zero-order release between 4~16 h and stability was excellent.]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHAG Jirui, DONG Yangyu, HAN Qing, QIN Chao and YIN Lifang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAG Jirui, DONG Yangyu, HAN Qing, QIN Chao and YIN Lifang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807008&flag=1]]></guid><cfi:id>50</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on formulation process of Sitagliptin Phosphate Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Screening the best prescription process of Sitagliptin Phosphate Tablets.<b>Methods</b>  Designing different prescription processes to determine the best prescription process by detecting dissolution profiles and powder data.<b>Results</b>  In the four prescriptions of the self-made tablets,the powder data and the fluency of the tablets were all good.Among them,the two prescriptions in the wet granulation process elute slower than the reference preparations,and the cross-linked carboxymethyl cellulose in the powder direct compression process.The dissolution curve was better with the reference formulation when the sodium sodium was 16 mg.<b>Conclusion</b>  Through the study on the formulation process of Sitagliptin Phosphate Tablets,the process and disintegrant dosage of Sitagliptin Phosphate Tablets were finally determined.]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Yanan, RAN Maoxiang and WANG Jing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yanan, RAN Maoxiang and WANG Jing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807009&flag=1]]></guid><cfi:id>49</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on stability of Enalapril Maleate Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To improve the stability of Enalapril Maleate Tablets.<b>Methods</b>  The enalapril maleate and sodium bicarbonate were dissolved in water at a molar ratio of 1:3 and used as a binder.<b>Results</b>  The compatibility test showed that the compatibility of the API with the excipients was good and the impurities did not change significantly.The 6-month accelerated test showed that the impurity C increased from 0.15% to 0.61% and the impurity D was from none-detection to 0.48%;12 months of long-term data showed that:impurity C increased from 0.15% to 0.42%, impurity D increased from none-detection to 0.1%.<b>Conclusion</b>  The results showed that the process can effectively solve the problem that the stability of enalapril maleate was not good.]]></description>
<pubDate>2018/7/6 16:37:44</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Yanan, RAN Maoxiang, WANG Jing and CHENG Ruiming]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yanan, RAN Maoxiang, WANG Jing and CHENG Ruiming</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806008&flag=1]]></guid><cfi:id>48</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of quality and stability study of different prescription process of nicergoline for Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Determine the factors influencing quality and stability of nicergoline for Injection and provide references for quality control of and stability under long-term storage condition.<b>Methods</b>  make products with different prescription and freeze-dry processing and test quality and stability at different temperatures, assess the impact of temperature on the related substance.<b>Results</b>  Water content and storage conditions will have an impaction to stability of nicergoline for injection.<b>Conclusion</b>  The water content and temperature are the main factors affecting the quality stability of nicergoline for injection, prescription difference affected is few.]]></description>
<pubDate>2018/7/6 16:37:44</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Xugui, WANG Peng, WEI Qianqian and WANG Jie]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Xugui, WANG Peng, WEI Qianqian and WANG Jie</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806009&flag=1]]></guid><cfi:id>47</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Homogenate extraction and quality evaluation of polysaccharides from <i>Dendrobium Officinale</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish the optimum process of homogenate extraction and quality standard of polysaccharides from <i>Dendrobium officinale</i>.<b>Methods</b>  Polysaccharides were obtained by homogenate extractor rapidly at room temperature. Liquid-solid ratio,extracting temperature and times were selected as independent variables of orthogonal test to determine the optimal process.The quality standard of <i>Dendrobium officinale</i> polysaccharides were determined by clustering analysis on contents and monosaccharide compositions of polysaccharides from 24 batches of <i>Dendrobium officinale</i>,<i>Dendrobium aphyllum</i> and <i>Dendrobium nobile</i> from different habitats.<b>Results</b>  The optimum parameters were as follows:liquid-solid ratio 30 mL·g<sup>-1</sup>,room temperature, extract for 3 times,2 min each time,after 30 min soaking.The content of the polysaccharides extracted from <i>Dendrobium officinale</i> by the optimal process was 70.68%~99.82% and the ratio of mannose to glucose was 3.75~25.60,which were quite different from those of <i>Dendrobium aphyllum</i> and <i>Dendrobium nobile</i>.<b>Conclusion</b>  The homogenate extraction process of polysaccharides from <i>Dendrobium officinale</i> was stable and efficient.The purity of the prepared <i>Dendrobium officinale</i> polysaccharides was not less than 70%,and the ratio of mannose to glucose was not less than 3.5.]]></description>
<pubDate>2018/6/13 9:41:48</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LI Beibei, CHEN Yueting, ZHU Mengxia and LU Yan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Beibei, CHEN Yueting, ZHU Mengxia and LU Yan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805007&flag=1]]></guid><cfi:id>46</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effect of endogenous enzymes in extraction process of baicalin from <i>Scutellaria baicalensis</i> Georgi with warm soaking extraction]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the effect of endogenous enzymes on the warm soaking extraction rate of baicalin from <i>Scutellaria baicalensis</i> Georgi.<b>Methods</b>  Warm soaking extraction of glycosides from <i>Scutellaria baicalensis</i> was adopted, high pressure steam inactivation method and water bath heating method were selected of for killing enzyme inactivation of baicalin within the original enzyme,the yield of baicalin in different samples under different conditions of enzyme inactivation was determined by HPLC.<b>Results</b>  High pressure steam inactivation group samples of baicalin showed the highest yield of 7.27%;Endogenous enzyme activity of baicalin group showed the lowest yield for 0.11%;In water bath heating to inactivate the enzyme group, the yield of baicalin increased in turn for 80,85 and 90 ℃ group sample.<b>Conclusion</b>  In the process of warm soaking extraction of <i>Scutellaria baicalensis</i> Georgi, the hydrolysis effect of endogenous enzyme on baicalin was strong;a high yield of baicalin could be obtained by the high pressure steam enzyme digestion.]]></description>
<pubDate>2018/6/13 9:41:48</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LI Yuejun and TANG Min]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Yuejun and TANG Min</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805008&flag=1]]></guid><cfi:id>45</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the technology of ultrafiltration of inorganic ceramic membrane for the refining of Jinyin Lidan Capsules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the optimum membrane pore size and the best operating conditions membrane while refining the water extracts of Jinyin Lidan Capsule by inorganic ceramic membrane.<b>Methods</b>  With water extracts of Jinyin Lidan Capsule as the research object, the refine effect was optimized under different liquid concentration and operating pressure with transfer rate of chlorogenic acid and membrane flux as evaluation index by single factor experiment method.<b>Results</b>  For this system,the membrane flux and transfer rate of chlorogenic acid were higher under the condition of pore size of 0.2 μm ceramic membrane,concentration of 0.05 g·mL<sup>-1</sup> and 0.6 MPa of operation pressure.<b>Conclusion</b>  The inorganic ceramic membrane had good applicability in the process of purifying the water extract of Jinyin Lidan Capsule,which laid the theoretical foundation for the later industrial production.]]></description>
<pubDate>2018/5/23 17:07:55</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LI Xinghuan<sup>1</sup>, JIA Tianqian<sup>1</sup>, LIU Hongbo<sup>2</sup>, REN Li<sup>1</sup> and SUN Jing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xinghuan<sup>1</sup>, JIA Tianqian<sup>1</sup>, LIU Hongbo<sup>2</sup>, REN Li<sup>1</sup> and SUN Jing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804008&flag=1]]></guid><cfi:id>44</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on similarity of dissolution curves of Vitamin E Nicotinate Capsules from different manufacturers]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The dissolution curves of vitamin E nicotinate capsules from different companies in China were investigated,and the similarities with the original preparations were compared to provide a reference for the generic pharmaceutical evaluation consistency.<b>Methods</b>  The dissolution process of Vitamin E Nicotinate capsules were monitored in the following repective medium: 1) water (contains 0.2%SDS), 2) hydrochloric acid solution with pH 1.2 (contains 0.2%SDS), 3) acetate buffer with pH 4.5 (contains 0.2%SDS), 4) citrate buffer with pH 6.8 (contains 0.2%SDS). The dissolution curves were determined by HPLC.The evaluation used the f2 factor method to further analyze the key factors affecting sample dissolution profiles.<b>Results</b>  The dissolution behaviors of the samples from four different companies inconsistent with the reference preparations in either dissolution medium.The dissolving particle size and the formulation process were the most critical factors affecting the dissolution of this product.<b>Conclusion</b>  It is recommended that relevant manufacturers should further optimize and improve the prescription process in order to improve the intrinsic quality of the product.]]></description>
<pubDate>2018/5/23 17:07:55</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WANG Wenxin<sup>1</sup>, HOU Airong<sup>2</sup>, NIE Yanjun<sup>1</sup>, NIU Chong<sup>1</sup> and XU Yuwen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Wenxin<sup>1</sup>, HOU Airong<sup>2</sup>, NIE Yanjun<sup>1</sup>, NIU Chong<sup>1</sup> and XU Yuwen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804009&flag=1]]></guid><cfi:id>43</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optimization of immobilized effect of chitosan microspheres on thrombin by the central composite design-response surface methodology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effects of chitosan microspheres on the immobilization of thrombin.<b.Methods</b>  The immobilized thrombin was prepared using chitosan microspheres as the carrier and glutaraldehyde as crosslinking agent.The optimum conditions of thrombin immobilized process were determined through central composite design-response surface methodology（CCD-RSM）by determining thrombin activity yield.<b>Results</b> The results showed that the optimum conditions of immobilized thrombin using chitosan microspheres were as follows: the concentration of thrombin and glutaraldehyde was 69.32 U·mL<sup>-1</sup> and 0.18%，immobilized time was 1.88 h,pH was 7.08,the thrombin activity yield was 81.55%.<b>Conclusion</b>  Chitosan microspheres have the positive immobilization effect on thrombin.]]></description>
<pubDate>2018/4/19 15:28:05</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[MIAO Yanli<sup>1</sup>, LI Weidong<sup>1</sup>, ZHONG Lilan<sup>1</sup>, LIAO Mingneng<sup>1</sup>, CHEN Shaohong<sup>2</sup>, LI Cuijuan<sup>1</sup> and LIN Zicheng<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MIAO Yanli<sup>1</sup>, LI Weidong<sup>1</sup>, ZHONG Lilan<sup>1</sup>, LIAO Mingneng<sup>1</sup>, CHEN Shaohong<sup>2</sup>, LI Cuijuan<sup>1</sup> and LIN Zicheng<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803008&flag=1]]></guid><cfi:id>42</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Particlesize distribution analysis of cilomilast using laser diffraction method]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the particle size distribution of cilomilast using laser diffraction method，and investigate the effect of different experimental conditions on the results.<b>Methods</b>  150 mg cilomilast was weighed,and added 20 mL 0.1% Tween-20 solution to disperse and take water as dispersant.The pump speed was 2 100 rpm.The particle refractive index and absorption index was 1.52 and 0.1,respectively.The dispersant refractive index was 1.33.Measurement time of background and sample was 12 seconds.<b>Results</b>  The d(0.1),d(0.5) and d(0.9) of three batches of sample was 16.552,16.235,16.417 μm;38.775,38.426,38.302 μm;71.455,71.487,71.279 μm.<b>Conclusion</b>  The method presented can be used to measure the particle size distribution of cilomilast with acceptable repeatability.]]></description>
<pubDate>2018/3/26 15:43:49</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZOU Wenbo, WANG Yan, YIN Lihui and HU Changqin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZOU Wenbo, WANG Yan, YIN Lihui and HU Changqin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802008&flag=1]]></guid><cfi:id>41</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[In vitro dissolution curves of Enalapril Maleate Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the dissolution behavior of Enalapril Maleate Tablets through the detection of dissolution curve,and reduce the risk of bioequivalence test.<b>Methods</b>  The dissolution profile of different Enalapril Maleate Tablets was determined to definite the prescription with the most similar dissolution profile to the reference formulation.<b>Results</b>  In the three prescriptions,the prescription with plus pregelatinized starch 8.64 mg was slower than the reference formulation, the prescription with plus pregelatinized starch 28.64 mg was faster than the reference formulation.The formulation with plus pregelatinized starch 18.64 mg was better fitted to the reference formulation.<b>Conclusion</b>  Through the dissolution curve of different prescriptions of Enalapril Maleate Tablets,compared with the reference formulation, the prescription that can be fit well to the reference formulation was screened,which effectively reduced enalapril maleate risk of bioequivalence testing.]]></description>
<pubDate>2018/3/26 15:43:49</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[RAN Maoxiang and LIU Yannan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>RAN Maoxiang and LIU Yannan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802009&flag=1]]></guid><cfi:id>40</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Determination of sulphate or chloride adulterated in illegal processed pangolin by ion chromatography]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish an ion chromatographic method for the determination of sulphate or chloride illegally added in the processed pangolin.<b>Methods</b>  The samples were analyzed on the IonPac AS11-HC(4 mm × 250 mm) exchange column. The mobile phase was 10 mmol·L<sup>-1</sup> potassium hydroxide solution. Inhibitory electrical conductivity detector was used with the flow rate as 1.0 mL·min<sup>-1</sup>.<b>Results</b>  The standard curves of sulphate and chloride were linear in the range of 0.1~100 μg·mL-1 (<i>r</i>=1.000).The average recovery of sulphate and chloride were 101.8% and 100.9%, and <i>RSD</i> were 2.2% and 2.4% (<i>n</i>=6),respectively.58 samples were detected using the established method. As a result,the sulphate content of 6 samples has severely exceeded the limits.<b>Conclusion</b>  This method was accurate and selective.It can be used to detect sulphate and chloride illegally added in the processed pangolin, supplying helpful information to detect the illegal weight gain of traditional Chinese medicine.]]></description>
<pubDate>2018/2/7 9:32:16</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Xiaoxiao<sup>1</sup>, LI Xue<sup>1</sup>, ZHANG Lidan<sup>1</sup> and WANG Lei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Xiaoxiao<sup>1</sup>, LI Xue<sup>1</sup>, ZHANG Lidan<sup>1</sup> and WANG Lei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801007&flag=1]]></guid><cfi:id>39</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Establishment of method for dissolution test of Ramelteon Tablet]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a method for evaluation of the dissolution profiles of self-made and original preparation of Ramelteon Tablet by f2.<b>Methods</b>  The paddle method was adopted with rotational speed of 50 rpm,using water,pH 1.0 hydrochloric acid solution.pH 4.5 acetate buffer solution and pH 6.8 phosphate buffer solution as dissolution media，HPLC was used to determine the cumulative dissolution of main components of self-made and original preparation of Ramelteon Tablet at different time points.Dissolution profile was drew，then f2 was used to evaluate its similarity.<b>Results</b>  In the 4 dissolution media,the of self-made and original preparation of Ramelteon Tablet was 72.30,64.25,78.00,68.92,respectively,which indicated that the dissolution profiles showed similarity.<b>Conclusion</b>  The established ray beauty for amine piece of in vitro dissolution behavior evaluation method for evaluation of ray beauty for amine piece of generic formulation was similar to the original development agent in vitro dissolution behavior,and of the ray for amine piece of prescription and technology of the imitation preparations had a certain guiding significance.]]></description>
<pubDate>2018/2/7 9:32:16</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Li<sup>1</sup> and HU Huasheng<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Li<sup>1</sup> and HU Huasheng<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801008&flag=1]]></guid><cfi:id>38</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and Pharmacodynamic study of ethosomes-based gels of the total flavonoids from Tibetan medicine “ZHAJIEESE”]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare ethosomes and ethosomes-based gels of the total flavonoids extract from Tibetan medicine ‘ZHAJIEESE’(ZJESF),and observe the effects of ZJESF ethosomes-based gels on hair growth and hair cycle of C57BL6 mouse alopecia model.<b>Methods</b>  The infusion method was used to prepare ZJESF ethosomes.ZJESF ethosomes-based gels was prepared by using carbomer as bases. Mouse alopecia model was established with C57BL/6J mice. To observe the effects of ZJESF ethosomes-based gels on hair growth and hair cycle of C57BL6 mouse.Results  ZJESF ethosomes-based gels were prepared with the optimal formulation and process.<b>Results</b>  The gels had uniform, fine, moderate consistency and good malleability of pale yellow semitransparent .The ZJESF ethosomes was pale yellow emulsion . The average particle size of the ethosomes was (296.6±5.8)nm, The Zeta potential was (-14.4±2.3)mv and the average encapsulation rate was 72.2%.In animal experiments, compared with the negative control group, ethosomes-based gels can accelerate the growth process of mice and achieve similar results in the positive control group.<b>Conclusion</b>  The formulation and preparation of ethosomes-based gels were feasible and reasonable. It’s quality was stable and controllable.Ethosomes-based gels can induce anagen and promote hair growth.The ethosomes-based gels had targeting of skin hair follicle sebaceous gland.]]></description>
<pubDate>2019/1/14 14:42:22</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[MEI Na, MAO Yu, XU Zuojun, MENG Da, CAI Meng, WANG Xiaoyao and DAI Weini]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MEI Na, MAO Yu, XU Zuojun, MENG Da, CAI Meng, WANG Xiaoyao and DAI Weini</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812007&flag=1]]></guid><cfi:id>37</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Quality evaluation of Flunarizine Hydrochloride Capsules by dissolution profiles in different dissolution mediums]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the dissolution profiles of domestic Flunarizine Hydrochloride Capsules and the reference preparation in four dissolution mediums, so as to evaluate the drug quality.<b>Methods</b>  The solubility and stability of flunarizine hydrochloride in pH 1.2 hydrochloric acid solution, pH 4.5 acetate buffer solution, pH 6.8 phosphate buffer solutions and water were investigated.The dissolution media of Flunarizine Hydrochloride Capsules were optimized and the dissolution profiles were determined by basket method at a rotated speed of 100 rpm. The results were compared and analyzed by <i>f</i><sub>2</sub> factor.<b>Results</b>  The imported localized Flunarizine Hydrochloride Capsules from manufacturer A were taken as reference preparation. The dissolution profiles of Flunarizine Hydrochloride Capsules from manufacturer B and E were similar to the reference preparation only in pH 1.2 hydrochloric acid solution, the dissolution process of preparations from manufacturer C was similar to reference preparation in pH 1.2 hydrochloric acid solution and water, and the dissolution profiles of flunarizine hydrochloride capsules from manufacturer D were similar to reference preparation in pH 1.2 hydrochloric acid solution and pH 4.0 acetate buffer. pH 4.0 acetate buffer was selected as the dissolution medium to determine the dissolution of Flunarizine Hydrochloride Capsules.<b>Conclusion</b>  There were differences in quality between domestic generic drugs and reference preparations, which still need to be improved in the prescription technology and control of drug production process.]]></description>
<pubDate>2018/12/3 10:00:45</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LI Qingcui<sup>1</sup>, XIE Yu<sup>1</sup> and GAO Ping<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Qingcui<sup>1</sup>, XIE Yu<sup>1</sup> and GAO Ping<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811008&flag=1]]></guid><cfi:id>36</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optimal extraction of effective constituents from <i>Rhizoma coptidis</i> and <i>Artemisia annua</i> in Qinglian Ningxin Capsules based on central composite design-response surface methodology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize the process of extracting effective constituents from <i>Rhizoma coptidis</i> and <i>Artemisia annua</i> by central composite design-response surface methodology.<b>Methods</b>  The effects of optimization factors such as solvent fold,ethanol concentration and extract time on extraction rate of berberine,palmatine,hydrastis and epiberberine of <i>Rhizoma coptidis</i> were investigated by using box-behnken design and response surface method;The effects of optimization factors such as solvent fold,ethanol concentration and warm immersion time on extraction rate of coefficient of unguent of <i>Artemisia annua</i> were investigated by using box-behnken design and response surface method.<b>Results</b>  The best extraction process of <i>Rhizoma coptidis</i> was 10.5 times of 70% ethanol with 1% H<sub>2</sub>SO<sub>4</sub> and extracting for three times,each time 90 min.Bias between the average content of berberine,palmatine,hydrastis,epiberberine and predicted values was less than -1.5%;The best extraction process of <i>Rhizoma coptidis</i> was 11.5 times of 60% ethanol with and extracting for two times,each time 110 min.Bias between the average content of artemisinin and predicted values was less than -0.33%.<b>Conclusion</b>  Optimized extraction technology of <i>Rhizoma coptidis</i> and <i>Artemisia annua</i> was convenient with high predictive．]]></description>
<pubDate>2018/10/18 9:58:38</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[MU Dake, MA Fei, MU Ranran and SUN Hongsheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MU Dake, MA Fei, MU Ranran and SUN Hongsheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201810008&flag=1]]></guid><cfi:id>35</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on rheological properties and release of Gatifloxacin Eye Thermosensitive Gel in vitro]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the rheological properties of Gatifloxacin Eye Thermosensitive Gel and sustained release in vitro.<b>Methods</b>  Rheometer was used to investigate rheological properties of Gatifloxacin Eye Thermosensitive Gel.The release of gatifloxacin from the gels was investigated by dialysis membrane method with Franz diffusion cel1.<b>Results</b>  Its gelling temperature was at 33 ℃；In vitro drug release studies showed that the sustained release effect of Gatifloxacin Eye Thermosensitive Gel was obvious, no sudden release effect was observed,and the accumulative drug release reached 61% within 12 hours.<b>Conclusion</b>  Gatifloxacin Eye Thermosensitive Gel has good thermal sensitivity and slow release in vitro.It is expected to be used in clinic.]]></description>
<pubDate>2019/8/30 17:59:12</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[SUN Tong<sup>1</sup>, XU Weina<sup>2</sup>, LENG Jiawei<sup>1</sup> and LI Yonggui<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Tong<sup>1</sup>, XU Weina<sup>2</sup>, LENG Jiawei<sup>1</sup> and LI Yonggui<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908007&flag=1]]></guid><cfi:id>34</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and photothermal property study of thiolated doxorubicin loaded hollow gold nanoparticles]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare a doxorubicin loaded hollow gold nanoparticles (HGNPs-DOX).<b>Methods</b>  Thiolated doxorubicin was synthesized, mass spectrum and hydrogen spectrum was used to characterize structure.Thiolated doxorubicin was loaded onto the surface of hollow gold nanoparticles using a covalent bond of Au-S. Particle size, surface plasmon resonance,transmission electron microscope, photothermal properties and cytotoxicity were performed to evaluate the doxorubicin loaded hollow gold nanoparticles system.<b>Results</b>  The molecular weight of the synthesized thiolated doxorubicin shown in MS ESI was 616 and the structure shown in <sup>1</sup>H-NMR was consistent with the target product. The doxorubicin loaded hollow gold nanoparticles had a particle size of 70 nm．The maximum absorption wavelength was about 800 nm and had good photothermal conversion ability. TEM showed the structure was a hollow spherical structure with a shell thickness of 4~6 nm. Cytotoxicity showed the doxorubicin loaded hollow gold nanoparticles could significantly reduced the toxicity of doxorubicin at higher concentrations.<b>Conclusion</b> HGNPs-DOX with good structure,photothermal conversion ability and less cytotoxicity was successfully synthesized. It can be used as a new generation promising delivery system for chemotherapy combined with photothermal therapy in the future.]]></description>
<pubDate>2019/7/26 10:27:48</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[YANG Ershuang, YANG Wenqian, XIA Yun and SHEN Yan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Ershuang, YANG Wenqian, XIA Yun and SHEN Yan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907006&flag=1]]></guid><cfi:id>33</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optimization of preparation technology of anticoagulant peptides by complex enzymatic hydrolysis of casein by central composite design-response surface method]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Using the central composite design-response surface method to optimize the preparation technology of anticoagulant peptides by complex enzymatic hydrolysis of casein,and  its  anticoagulant activity and thrombolytic effect in vitro were determined.<b>Methods</b>  First,the central composite design-response surface method was used to determine the optimal reaction conditions for the hydrolysis of casein by four enzymes bromelain,trypsin,pancreatic chymotrypsin,and papain.Then,the casein complex enzymatic hydrolysis is obtained by complex enzymatic hydrolysis of casein under the optimal reaction conditions of each enzyme.The thrombin titration modification method was used to determine the anticoagulant activity in vitro and the casein complex enzymatic hydrolysate with the highest anticoagulant activity was used for in vitro thrombolytic experiments.<b>Results</b>  The optimal reaction conditions of the four enzymes for hydrolyzing casein are as follow, bromelain:pH was 6.50,temperature was 60.00 ℃,enzyme dosage was 12 000.00 U/g,time was 3.00 h, material to water ratio was 1:7(m/V); trypsin and pancreatic chymotrypsin: pH was 8.00,temperature was 50.00 ℃, enzyme dosage was 6000.00U/g,time was 3.00h,material to water ratio was 1:7(m/V); papain: pH was 6.50, temperature was 60.00 ℃,enzyme dosage was 4 000.00 U/g,time was 3.00h, material to water ratio was 1:7(m/V).<b>Conclusion</b>  Under the experimental condition, the casein enzymolysis solution obtained by the combination of the four enzymes-bromelain, trypsin, pancreatic chymotrypsin, and papain-has the highest anticoagulant activity (100.0 ATU/mL);The casein enzymolysis solution with highest anticoagulant activity can completely dissolve the rabbit thrombus line after soaking for 24 h. And when New Zealand white rabbit blood and the casein enzymolysis solution ratio (V/V) was 1:1 and 4:6, the blood still did not coagulate after 48 h.]]></description>
<pubDate>2019/6/27 10:49:43</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WU Xiong<sup>1</sup>, XIA Jiankai<sup>1</sup>, MIAO Yanli<sup>1</sup>, CHEN Shaohong<sup>2</sup>, ZHANG Zhaoxia<sup>1</sup>, GUO Wanting<sup>1</sup> and LI Lingling<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Xiong<sup>1</sup>, XIA Jiankai<sup>1</sup>, MIAO Yanli<sup>1</sup>, CHEN Shaohong<sup>2</sup>, ZHANG Zhaoxia<sup>1</sup>, GUO Wanting<sup>1</sup> and LI Lingling<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906007&flag=1]]></guid><cfi:id>32</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on preparation for Benidipine Hydrochloride Dropping Pills]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish the best forming preparation process for Amlodipine Besylate dropping pills.<b>Methods</b> Indicators for the evaluation of mixed status,subsidence,forming conditions,coefficient of variation,etc.The impact of the oill formability such asthe different kinds of primary substance,refrigerant,liquid temperature,speed,distance,refrigerant,using L<sub>9</sub> (3<sup>4</sup>) orthogonal design the best molding process.<b>Results</b>  The best quality pills forming the conditions of using polyglycol-6000,liquid temperature of 80 ℃,drip system speed of 45～50 drops per minute, drip distance of8 cm, condensing temperature is 10～12 ℃.<b>Conclusion</b>  This preparation method was suitable for both the laboratory test and the industrial production for Amlodipine Besylate dropping pill．]]></description>
<pubDate>2019/6/3 16:05:48</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHOU Weili, ZHAO Fangjun, ZHAO Yanxia and GONG Weihong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Weili, ZHAO Fangjun, ZHAO Yanxia and GONG Weihong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905007&flag=1]]></guid><cfi:id>31</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and quality research for Myricetin Tablets and Dihydromyricetin Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the prescription composition and preparation process for Myricetin Tablets and Dihydromyricetin Tablets.<b>Methods</b>  Myricetin Tablets and Dihydromyricetin Tablets were prepared by wet granulation and tableting technology. The disintegration time of Myricetin Tablets and Dihydromyricetin Tablets was determined respectively, and their content was determined by ultraviolet-visible spectrophotometry.<b>Results</b>  Myricetin Tablets and Dihydromyricetin Tablets were prepared by adding CMS-Na into the tablets by internal and external addtion. After coating, their disintegration time was 15 min and 10 min, respectively. Their contents were 94.09 mg and 109.35 mg respectively, within the limits of 100%±10% of the labeled amount.<b>Conclusion</b>  The preparation process for Myricetin Tablets and Dihydromyricetin Tablets were feasible, which laid a foundation for their investigation of bioavailability and pharmaceutical application.]]></description>
<pubDate>2019/5/10 16:54:54</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Dongsheng<sup>1</sup>, GAO Rong<sup>1</sup> and CHEN Fangzhao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Dongsheng<sup>1</sup>, GAO Rong<sup>1</sup> and CHEN Fangzhao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904007&flag=1]]></guid><cfi:id>30</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Qualitative and quantitative study of Pudilan Xiaoyan Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a method for the quality control of Pudilan Xiaoyan Tablets.<b>Methods</b>  Microscope,TLC were used to identify the contents of <i>Scutellaria baicalensis</i> Georgi,dandelion,<i>Corydalis bungeana</i>,<i>Radix Isatidis</i>;HPLC was used to measure the effective content of baicalin in <i>Scutellaria baicalensis</i> Georgi,C<sub>18</sub> column,the mobile phase was methanol-water-phosphoric acid (47:53:0.2),the wavelength was 280 nm,and the flow rate was 1.0 mL·min<sup>-1</sup>.<b>Results</b>  The contents of <i>Scutellaria baicalensis</i> Georgi,dandelion,Corydalis bungeana,Radix Isatidis can be detected by TLC,baicalin showed a good linear in the range of 5.00 8～100.16 µg(<i>r</i>=0.999 8),the average recovery of baicalin was 98.87%,<i>RSD</i>=0.95%(<i>n</i>=9). <b>Conclusion</b>  The method was sample,reliable,and can be used for the quality control of Pudilan Xiaoyan Tablets.]]></description>
<pubDate>2019/3/29 12:07:29</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[JIANG Huizhen, LIU Xuejie, WANG Jundong, CUI Xiaofei, LIU Xiaojing, LI Xingchen and LI Junqiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Huizhen, LIU Xuejie, WANG Jundong, CUI Xiaofei, LIU Xiaojing, LI Xingchen and LI Junqiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902007&flag=1]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Quality evaluation and influencing factors analysis of domestic oral oxacillin sodium]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the quality status of domestic oral oxacillin sodium (tablets and capsules) and analyze the influencing factors of the quality of the product.<b>Methods</b>  For the sample in 2016, the experiment was carried out by means of statutory inspection combined with exploratory research, and the statistical data were analyzed.<b>Results</b>  Statutory tests showed 12batches of samples were all qualified.The exploratory research combined with the statistical analysis found that the quality of raw materials, production process level were closely effected the product of key quality factors ,such as moisture, related substances, dissolution, were the the key process parameters of the product. <b>Conclusion</b>  At present,the Chinese Pharmacopoeia 2015 edition meets the quality control requirement of this product.The quality of capsules is better than that of sugarcoated tablets.It is suggested that enterprises should attach importance to the quality of raw materials, optimize the production process, enhance process control and improve product quality.]]></description>
<pubDate>2019/3/1 11:18:19</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHANG Dousheng, WANG Chen, WANG lixin, CHONG Xiaomeng, YAO Shangzhen and XU Mingzhe]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Dousheng, WANG Chen, WANG lixin, CHONG Xiaomeng, YAO Shangzhen and XU Mingzhe</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901007&flag=1]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on related substances of Escitalopram Oxalate Tablets and its influencing factors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effects of temperature,humidity,excipient,packaging materials and water activity on related substances in Escitalopram Oxalate Tablets and provide reference for determining preparation process and storage conditions.<b>Methods</b>  The related substances and water activity under different experimental condition of the samples were analyzed by HPLC and water activity tester.<b>Results</b>  Degradation of the sample was significantly faster under high temperature and humidity conditions,Microcrystalline cellulose, silica and magnesium stearate could accelerate sample degradation.The quality of the packaging material directly affected the stability of the sample.<b>Conclusion</b>  It was recommended that the companies should control water in production process,reduce the use of MCC,silica and magnesium stearate,use good seal packaging material or add desiccant, avoid high temperature and humidity during the storage process.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[NIE Yanjun, WANG Wenxin, ZHENG Jing, DOU Yanli and XU Yuwen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>NIE Yanjun, WANG Wenxin, ZHENG Jing, DOU Yanli and XU Yuwen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901008&flag=1]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[大豆分离蛋白基共聚物SPI/AGC水凝胶的制备研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/15 9:11:55</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[杨英,杨艳丽]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨英,杨艳丽</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910006&flag=1]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bioequivalence tests of Cetirizine Hydrochloride Teblets in healthy volunteers]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the bioequivalence of preparations and reference subjects in a single dose of cetirizine hydrochloride tablets under fasting and postprandial conditions in healthy volunteers.<b>Methods</b>  A random, open label, single-dose, self-crossover  test was designed. LC-MS/MS was applied to determine the concentration of cetirizine in plasma of healthy subjects after fasting or postprandial administration, while PHOENIX WINNONLIN 8.0 and SAS 9.4 software were used for pharmacokinetics (PK) parameters calculation and bioequivalence analysis, respectively.<b>Results</b>  In the fast test, 24 healthy subjects took the test preparation and the reference preparation 10 mg on a single fasting. The ratio of the geometric mean of Cmax, AUC0-t, AUC0-∞ are 100.18%, 96.37%, 96.00%, respectively. The 90% confidence intervals of Cmax, AUC0-t, AUC0-∞ are 95.72% ~ 14.84%, 92.37% ~ 100.55%, 91.77% ~ 100.42%, respectively. All these data are falling within the equivalent interval of 80.00% ~ 125.00%. In the postprandial test, 22 healthy subjects took the test and reference preparations 10 mg after a single meal. The ratio of the geometric mean of Cmax, AUC0-t, AUC0-∞ are 103.98%, 102.19% 101.58%, respectively, with 90% confidence intervals of 98.31% ~ 109.97%, 98.33% ~ 106.20%, 98.07% ~ 105.20%, respectively, all of which are falling within the equivalent range of 80.00% ~ 125.00%.<b>Conclusion</b>  The two formulations are bioequivalent to healthy adult volunteers under fasting and postprandial conditions.]]></description>
<pubDate>2020/9/30 14:34:46</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[SI Ge<sup>1</sup>, GUO Jianyan<sup>2</sup>, ZHANG Honghen<sup>2</sup>, GAO Juan<sup>3</sup>, ZHENG Zhonghui<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SI Ge<sup>1</sup>, GUO Jianyan<sup>2</sup>, ZHANG Honghen<sup>2</sup>, GAO Juan<sup>3</sup>, ZHENG Zhonghui<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009006&flag=1]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on forming process for Yinhua Ganmao Dropping Pills]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the optimum preparation for Yinhua Ganmao Dropping Pills.<b>Methods</b>  The preparation conditions, such as mixing condition, settlement, appearance quality, the time of dissolution and pill weight difference etc. were studied with L<sub>9</sub>(3<sup>4</sup>) orthogonal to design the best primary substance,the proportion between the medicine and primary substance,melting temperature and cooling agent.The drop temperature,cooling temperature, dropping speed and dropping distance were selected according to the total score of drop pills. <b>Results</b>  The best preparation process of Yinhua Ganmao Dropping Pills was to take the mixture of PEG 4000 and PEG 6000 (1:1) as the matrix, the extract and the matrix (1:3.5) were dissolved at 80℃ and then drop into 10℃ dimethylsilicone oil at a distance of 6 cm and 35 drops/min.<b>Conclusion</b>  The quality of Yinhua Ganmao Dropping Pills met the requirements, and the preparation process was reasonable and feasible.]]></description>
<pubDate>2020/8/26 16:19:33</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WANG Haiye<sup>1</sup> and WANG Hong<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Haiye<sup>1</sup> and WANG Hong<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008007&flag=1]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Methodological study of partical size distribution of Intermediate products of isosorbide mononitrate sustained-release tablets by laser particle analyzer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish an experimental method for the measurement of the particle size distribution of isosorbide mononitrate sustained release tablets intermediate products.<b>Methods</b>  The Malvern Mastersizer 3000 type laser size analyzer was equipped with a MAZ3500 dry autosampler were used. The determination conditions were investigated as follows: sample refractive index of 1.52, funnel gap 1.0 mm, shading degree of 0.8%-3.0%, dispersed gas pressure 2.0 bar, sample measurement time 25 s.<b>Results</b>  For the same batch of test samples, the <i>RSD</i> value of the particle size distribution results measured by different operators using the same instrument and the same method is less than 1.0%,and the same operator uses the same instrument and the same method to measure the three batches of test samples.The inter-batch <i>RSD</i> value of the particle size distribution result is less than 2.0%.<b>Conclusion</b>  The method with good reproducibility, high accuracy and simple operation can be used for the particle size analysis of the intermediate product of isosorbide mononitrate sustained-release tablets.]]></description>
<pubDate>2020/5/6 16:00:46</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[XUN Mingjin, FENG Zhong, ZHANG Guimin, LI Wenfang and ZHANG Xiaobo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XUN Mingjin, FENG Zhong, ZHANG Guimin, LI Wenfang and ZHANG Xiaobo</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004006&flag=1]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[奥美沙坦酯片的制备及其溶出曲线研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/4/20 13:55:10</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[孔凡强,程宏霞,卢伟伸,周振宇]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孔凡强,程宏霞,卢伟伸,周振宇</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003007&flag=1]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[挤出法3D打印对乙酰氨基酚片的可行性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 14:28:10</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[张关璇子<sup>1</sup>,刘伯石<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张关璇子<sup>1</sup>,刘伯石<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002008&flag=1]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optimization the extraction technology of Xuanyu Tongjingtang Granules by orthogonal test]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize the extraction technology of Xuanyu Tongjintang  Granules.<b>Methods</b>  The amount, time and times of water extraction of Xuanyu Tongjintangg Granules were optimized by orthogonal test. The content of paeoniflorin in the extract and the dry extract rate were taken as the index, and each factor had three levels to optimize the water extraction process.<b>Results</b>  The best water extraction process of Xuanyu Tongjintang granules is to soak the decoction pieces in 8 times water for 30 minutes, extract them three times, each time for 60 minutes.<b>Conclusion</b>  The optimized extraction process of Xuanyu Tongjintang Granules is stable and feasible.]]></description>
<pubDate>2020/12/7 15:11:54</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[刘群<sup>1</sup>，刘伟<sup>2</sup>，姜大勇<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘群<sup>1</sup>，刘伟<sup>2</sup>，姜大勇<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011006&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and In vitro Release of Mesalamine Delayed-release Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare mesalamine delayed-release tablets and investigate the in vitro release behaviors. <b>Methods</b>  With the similarity factor (<i>f</i><sub>2</sub>) in vitro release as the evaluation index,the optimal formulation was determined by single factor experiments and orthogonal experiments. Three batches of mesalamine delayed-release tablets were reproduced and compared with the reference listed drug. <b>Results</b>  The amount of sodium carboxymethylcellulose(CMC 7HXF PH) was 45mg and the amount of sodium starch glycolate(CMSNa) was 35mg in the tablet core. The ratio of Eudragit L100 to Eudragit S100 was 2:3 and the coating weight gain was 6% in the enteric coating shell. The <i>f</i><sub>2</sub> values were all greater than 50. <b>Conclusion</b>  The release behaviors of the self-made mesalamine delayed-release tablets and the reference listed drug are similar. The formulation and preparation process are stable and reproducible,which can be applied to prepare mesalamine delayed-release tablets .]]></description>
<pubDate>2021/8/16 15:40:09</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHAO Shijuan, YAN Jiarui, SHI Ting, YAN Zhen, YIN Lifang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Shijuan, YAN Jiarui, SHI Ting, YAN Zhen, YIN Lifang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107007&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the preparation technology of Shengyang Yiwei granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> to optimize the extraction and molding technology of Shengyang Yiwei granules. <b>Methods</b>  Taking the content of Liquiritin and Paeoniflorin as indexes, the water extraction process of Shengyang Yiwei granules was optimized and verified 3 times, and the wettability and excipient were optimized with the rate of finished granules and Operability as indexes, pilot-scale production of 3 batches of products with 160 times the prescribed quantity.<b>Results</b>  The extraction process of Shengyang Yiwei granules was water extraction 3 times, adding 8 times water each time, decocting for 30 minutes, and the excipients were sugar powder, alcohol and soluble starch, the granules were prepared with low concentration of ethanol, the rate of finished granules was stable, the contents of liquiritin and Paeoniflorin were stable. <b>Conclusion</b>  The optimum technology of Shengyang Yiwei granule is stable and feasible.]]></description>
<pubDate>2021/8/16 15:40:09</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WANG Hong<sup>1</sup>, MA Quanlong<sup>2</sup>, JIANG Liang<sup>3</sup>, LI Peng<sup>3</sup>, WANG Kun<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Hong<sup>1</sup>, MA Quanlong<sup>2</sup>, JIANG Liang<sup>3</sup>, LI Peng<sup>3</sup>, WANG Kun<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107008&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[激光散射法测定羧甲纤维素钙粒度与粒度分布的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:19</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[王松，谭会洁，张丹丹，李宁宁，陈德俊]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王松，谭会洁，张丹丹，李宁宁，陈德俊</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106008&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research on forming process of Compound Carambola Granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To select the forming process of compound carambola granules.<b>Methods</b>  The moisture absorption rate, molding rate and melt examination was used as the index to select appropriate excipient and its formulas，finally determine the optimum preparation formation process.<b>Results</b>  The best process conditions were as follows, extract: soluble starch: dextrin=1:1:0.2, the wetting agent was 90% alcohol. Preparation and evaluation of 3 batches of particles according to the molding process. The forming rate of particles can reach more than 80%, Determination of moisture content and melting property of granularity check are in compliance with regulations and particle critical relative humidity (CRH) is 66.91%.<b>Conclusion</b>  The forming preparation process is feasible and rational, which provides a scientific experimental basis for large-scale production.]]></description>
<pubDate>2021/5/25 19:40:51</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[JIANG Luhui, LI Yuchun, CHEN Lixiu, LIANG Peng, HUANG Renbin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Luhui, LI Yuchun, CHEN Lixiu, LIANG Peng, HUANG Renbin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104007&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on quality standard of <i>Tetrastigma hemsleyanum</i> Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the quality standard of the <i>Tetrastigma hemsleyanum</i> Tablets (THT), and provide the foundation for its quality control. <b>Methods</b>  Using thin-layer chromatography (TLC) to identify orientin, isoorientin, vitexin, vitexin-2-O-rhamnoside and isovitexin in THT; Triethylamine color development with UV-Vis spectrophotometry was used to determine the content of total flavonoids in the THT;High performance liquid chromatography (HPLC) was established to determine 8 major components (orientin, isoorientin, vitexin, vitexin-2-O-rhamnoside, isovitexin, chlorogenic acid, neochlorogenic acid and cryptochlorogenic acid), Welch Ultimate XB-C<sub>18</sub> column (4.6 mm×150 mm, 2.7 μm), gradient elution, detection wavelength:330 nm, flow rate: 0.4 mL·min<sup>-1</sup>.<b>Results</b>  TLC to identify orientin, isoorientin, vitexin, vitexin-2-O-rhamnoside, and isovitexin in the THT using the developing agent ethyl acetate: formic acid: toluene: water = 8:1:1:1, after AlCl<sub>3</sub> color development, inspection under ultraviolet light 365 nm;UV-Vis method to determine the total flavonoids content, there is a good linear relationship with the absorbance value at the range of 1.85~11.1 μg mL<sup>-1</sup> of vitexin, and the average recovery was 98.43% with the <i>RSD</i> 2.46%. The established HPLC method showed a good linear relationship between the concentration of the 8 components to their peak areas (<i>r</i>>0.999 0) within the investigated concentration. The average recovery was 96.88%~99.25%, and the <i>RSD<i/>s were 1.94%~2.47%.<b>Conclusion</b>  In this experiment,the TLC method for THT was established to identify orientin, isoorientin, vitexin, vitexin-2-O-rhamnoside and isovitexin in the THT;UV-Vis was used to determine the content of total flavonoids, and HPLC methods was used to determine the content of 8 components in the THT, which provided a reference for the quality control of it.]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHOU Yuheng<sup>1,2</sup>, XU Huilong<sup>1,2</sup>, SU Lan<sup>1,2</sup>, YU Jiamin<sup>1</sup>, XU Wen<sup>1,2</sup>, FAN Shiming<sup>1,2</sup>, XU Wei<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Yuheng<sup>1,2</sup>, XU Huilong<sup>1,2</sup>, SU Lan<sup>1,2</sup>, YU Jiamin<sup>1</sup>, XU Wen<sup>1,2</sup>, FAN Shiming<sup>1,2</sup>, XU Wei<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103008&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and quality evaluation of Camptothecin -loaded Pluronic 105 and TPGS mixed micelles]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prepare camptothecin-loaded Pluronic 105 and D-α-tocopheryl polyethylene glycol 1000 succinate micelles and evaluate their properties and the in vitro release behavior.<b>Methods</b>  In terms of the molar radio of polymers,we prepared four formulations micelles using film formation method.The properties of micelles such as shape,particle size and size distribution were observed by transmission electric microscope and the laser dynamic scattering method.The assaying of the CPT-loaded mixed micelles was detected with spectrofluorometry.The in vitro release of the polymeric mixed micelles was evaluated using a dialysis method.<b>Results</b>  Pictures by transmission electron microscopy revealed spherical and core-shell CPT-loaded P105/TPGS micelles.The hydrodynamic radius range of the four kinds of polymeric micelles was from 4 to 9 nm,and an centralized micelllar size was observed with the increasing amounts of TPGS. The solubility of camptothecin was significantly improved by mixed micelles. The release rate of camptothecin mixed micelles was slow in vitro, which could be described by double phase dynamic model.<b>Conclusion</b>  Mixed micelles made of Pluronic 105 and TPGS may serve as nanoscopic,long-circulating carriers for sparingly soluble anticancer drugs.]]></description>
<pubDate>2021/3/1 14:21:04</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WEI Pei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Pei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101006&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[替米沙坦氨氯地平片处方研究及溶出行为考察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/31 9:04:44</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[徐斌<sup>1</sup>，崔萍<sup>1</sup>，丁逸梅<sup>1,2</sup>，周卫<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>徐斌<sup>1</sup>，崔萍<sup>1</sup>，丁逸梅<sup>1,2</sup>，周卫<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112006&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[聚丙烯安瓿包装盐酸氨溴索注射液相容性试验—抗氧剂的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/31 9:04:44</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[于洪华<sup>1</sup>，赵同申<sup>1</sup>，颜红<sup>2</sup>，丁锐<sup>1</sup>，杨清华<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>于洪华<sup>1</sup>，赵同申<sup>1</sup>，颜红<sup>2</sup>，丁锐<sup>1</sup>，杨清华<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202112007&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[替加环素脂质体的制备工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/10 9:23:29</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[XU Yanyan<sup>1</sup>, ZHENG Lijun<sup>2</sup>, ZHANG Xiayan<sup>1</sup>, WU Zhenbo<sup>1</sup>, ZHU Yanyan<sup>1</sup>, WANG Haixiang<sup>2</sup>, TIAN Jilai<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Yanyan<sup>1</sup>, ZHENG Lijun<sup>2</sup>, ZHANG Xiayan<sup>1</sup>, WU Zhenbo<sup>1</sup>, ZHU Yanyan<sup>1</sup>, WANG Haixiang<sup>2</sup>, TIAN Jilai<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111007&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[银花感冒颗粒（无糖型）的成型制备工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/10 9:23:29</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIN Xiao<sup>1</sup>, QIN Changjin<sup>2</sup>, XIE Xiaoyan<sup>3</sup>, WANG Haoye<sup>4</sup>, WANG Kun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Xiao<sup>1</sup>, QIN Changjin<sup>2</sup>, XIE Xiaoyan<sup>3</sup>, WANG Haoye<sup>4</sup>, WANG Kun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111008&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Determination of EquilibriumSolubility , Oil-water Partition Coefficient and Dissociation Constant of Sempervirine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The equilibrium solubility and oil-water distribution coefficient of sempervirine (SPV) in phosphate buffers (PBS) with different pH values were determined, and the dissociation constant of sempervirine was investigated, which provided some basis for the development of preparation of sempervirine.<b>Methods</b>  Ultra high performance liquid chromatography (UPLC) and flask shaking method were used to determine the equilibrium solubility of sempervirine and the oil-water distribution coefficient of n-octyl alcohol-PBS in different pH. The dissociation constant of sempervirine was determined by ultraviolet spectrophotometry. <b>Results</b>  The solubility of sempervirine in PBS at pH 1.2~7.4 ranged from 285.356 mg×L<sup>-1</sup> to 557.945 mg×L<sup>-1</sup>, and the oil-water distribution coefficient ranged from 0.316 to 5.803. The dissociation constant pKa is 11.10. <b>Conclusion</b>  The pH value affects the equilibrium solubility and oil-water distribution coefficient of sempervirine, and the low solubility and dissociation constant of sempervirine may affect its in vivo absorption.]]></description>
<pubDate>2021/11/11 17:05:07</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[JIANG Wenwen, ZHANG Yuanjie, LI Gaopan, SONG Yu, WU Shuisheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Wenwen, ZHANG Yuanjie, LI Gaopan, SONG Yu, WU Shuisheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202110007&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Studies on the optimization of the preparation process of Shenbai Nanosuspension based on effective parts and the effect of increasing leukocyte]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize the preparation process of nanosuspension based on the effective parts of Shenbai formulation, and characterize the nanosuspension, and study the efficacy of increasing leukocyte.<b>Methods</b>  The total polysaccharides and total saponins in Shenbai formulation were selected as the effective part of Shenbai nanosuspension. On the basis of single factor investigations, taking the stabilizer dosage, homogenization pressure and homogenization times as the influencing factors, the orthogonal optimization of the preparation process of Shenbai nanosuspension was carried out by the high-pressure homogenization method. Concurrently, settlement stability was observed. And the prepared nanosuspension was characterized and the efficacy test of increasing leukocytes was researched. <b>Results</b>  The optimal preparation process of Shenbai effective part nanosuspension was as follows: the mass ratio of drug to soybean lecithin 1:1.75, the homogenization pressure 700bar, and the homogenization times with 14 times. The particle size of the nanosuspension was (277.3±2.17) nm, and the PDI was 0.185±0.018 with the Zeta potential (-32.50±0.86) mV. Compared with the model group, after 7 days of administration, the level of leukocytes in the high-dose SBEP-NS group increased significantly, and after 15 days, the level of leukocytes in each dose group increased significantly(<i>P</i><0.05). <b>Conclusion</b>  The preparation process of Shenbai effective part nanosuspension is reasonable and feasible. The particle size in the suspension meets nanoparticle requirement with an uniform dispersion and good stability. Meanwhile, the nanosuspension has a positive effect in increasing leukocyte. In a word, the paper provides useful enlightenment for the new drug research of traditional Chinese medicine nanosuspension composed of effective parts.]]></description>
<pubDate>2022/7/19 16:37:41</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[JIAN Fengjiao, GUO Min, WU Peihang, LI Xiaodong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIAN Fengjiao, GUO Min, WU Peihang, LI Xiaodong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206006&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on preparation technology for Rukuai Sanjie Granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To screen the preparation technology of Rukuai Sanjie Granules.<b>Methods</b>  The water extraction process of Rukuai Sanjie Granules was selected by orthogonal test with Danshensu transfer rate as index, and the concentration of alcohol, the resting time and excipient of the granules were investigated.<b>Results</b>  The best extraction process of Rukue Sanjie Granules was 2 hours each time with 8 times water, 75% alcohol concentration and 48 hours rest time, and the excipients were soluble starch and dextrin(1:1).<b>Conclusion</b>  The optimum preparation technology of Rukuai Sanjie Granules is stable and feasible.]]></description>
<pubDate>2022/7/19 16:37:41</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[ZHOU Weili, SUN Tong, WANG Kun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Weili, SUN Tong, WANG Kun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206007&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation of Berberine Hydrochloride Enteric Coated Sustained Release Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the preparation of Enteric-coated Sustained-release Tablets of Berberine Hydrochloride.<b>Methods</b>  Using the in vitro release evaluation method, the formula and process of berberine hydrochloride enteric-soluble sustained release tablets were screened by single factor design and orthogonal design, and the tablets were coated with Enteric-coating. Berberine hydrochloride enteric-soluble sustained-release tablets were prepared.<b>Results</b>  In vitro release test showed that both core and enteric-coated tablets fit Higuchi's drug release model.<b>Conclusion</b>  The technology of Enteric-coated Sustained-release Tablets of Berberine Hydrochloride is stable; in vitro drug release meet the design requirements .]]></description>
<pubDate>2022/6/8 14:30:15</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIN Qingwei<sup>1</sup>, ZHONG Hualin<sup>1</sup>, LI Peibo<sup>1</sup>, WU Hao<sup>1</sup>, PENG Wei<sup>1</sup>, SU Weiwei<sup>1</sup>, CHENG Chunlei<sup>2</sup>, WANG Yonggang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Qingwei<sup>1</sup>, ZHONG Hualin<sup>1</sup>, LI Peibo<sup>1</sup>, WU Hao<sup>1</sup>, PENG Wei<sup>1</sup>, SU Weiwei<sup>1</sup>, CHENG Chunlei<sup>2</sup>, WANG Yonggang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205006&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and Characterization of Remdesivir Polymeric Nanomicelles]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The purpose of this article is to prepare the Remdesivir nanomicelles (RNM) and investigate its physico-chemical properties in vitro. <b>Methods</b>  RNM was made up of biodegradable mPEG-b-PDLLA copolymer and was prepared by solid dis-persion method. The morphology and particle size of RNM was investigated by transmission electron microscopy (TEM) and Malvern laser particle size analyzer. The characters including drug loading and encapsulation efficiency were detected by X-ray diffraction (XRD) and High-performance liquid chromatography (HPLC). A dialysis method was used to determine the in vitro release behaviors of RNM. <b>Results</b>  The micelles are well dispersed as individual nanoscale micelles with regularly spherical shape. The particle size and polydisperse index of RNM were 12.97±1.33 nm and 0.062±0.023, respectively. Drug loading and encapsulation efficiency reached 10%±0.33% and 99.25%±0.86%. RNM exhibited sustained-release action in vitro.<b>Conclusion</b>  The mPEG-b-PDLLA micelles loaded remdesivir were successfully prepared. In vitro experiments showed that RNM significantly enhanced solubility of remdesivir and released remdesivir at a controlled rate. RNM should hold great potential for developing a novel formulation.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[WU Haijun<sup>1</sup>, LI Yufeng<sup>2</sup>, ZHONG Qiang<sup>3</sup>, ZHANG Guangtao<sup>3</sup>, MA Chunlei<sup>3</sup>, XIE Jizhen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Haijun<sup>1</sup>, LI Yufeng<sup>2</sup>, ZHONG Qiang<sup>3</sup>, ZHANG Guangtao<sup>3</sup>, MA Chunlei<sup>3</sup>, XIE Jizhen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203007&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effect of excessive lubrication of magnesium stearate on metformin hydrochloride sustained-release tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The effect of excessive lubrication of magnesium stearate on metformin hydrochloride sustained-release tablets was investigated. <b>Methods</b>  By changing the dosage of magnesium stearate, changing the mixing time of magnesium stearate, and changing the speed of the feeder, different metformin hydrochloride sustained-release tablets were prepared. By comparing the powder properties of the total mixed granules and the dissolution of tablets. Objective to evaluate the effect of magnesium stearate over lubrication on metformin hydrochloride sustained release tablets. <b>Results</b>  Increasing the amount of magnesium stearate, prolonging the total mixing time, and speeding up the speed of the feeder will all lead to excessive lubrication of magnesium stearate. The fluidity of the particles has not been significantly improved, but the compressibility is significantly reduced, and the dissolution of metformin hydrochloride sustained-release tablets does not slow down significantly.<b>Conclusion</b>  The compressibility of metformin hydrochloride sustained-release tablets is sensitive to the lubricating effect of magnesium stearate. It is necessary to control the amount of magnesium stearate, the mixing time, and the feeder transfer to prevent excessive lubrication, resulting in poor compressibility.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[FU Qingshuang, LI Kunwei, WANG Yingjuan, HUANG Guoying, ZHANG Tian, CHANG Huijun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FU Qingshuang, LI Kunwei, WANG Yingjuan, HUANG Guoying, ZHANG Tian, CHANG Huijun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203008&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation, quality evaluation and in vitro transdermal properties of Bulleyaconitine A dissolving microneedles]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  In order to overcome the side effects of the existing administration methods of bulleyaconitine a, the preparation technology, characterization and in vitro transdermal properties of bulleyaconitine a dissolving microneedles were studied. <b>Methods</b>  The dissolving microneedles of bulleyaconitine a were prepared by layered pouring method, and the optimal formulation and preparation technology were optimized by orthogonal design. The quality of microneedles was evaluated, such as the appearance, mechanical strength, drug loading, transdermal release, etc. <b>Results</b>  The optimal formulation and preparation process of bulleyaconitine a dissolving microneedles were as follows: 35% ethanol solution as solvent, 0.3 g/mL hyaluronic acid (HA) and polyvinylpyrrolidone (PVP K30) (4:6) mixed solution, 15% polyvinyl alcohol (PVA) solution as backing substrate, and drying at 35 ℃ to prepare microneedles with drug contents of 150 μg, 100 μg and 70 μg, respectively. The results showed that the microneedles had good mechanical strength, and could successfully pierce aluminum foil and pig skin; in vitro transdermal study showed that the drug release of microneedles was 84.67% at 24 h and 96.41% at 48 h. <b>Conclusion</b>  The layered dissolving microneedles of bulleyaconitine a are successfully prepared, which can achieve effective transdermal delivery and sustained-release effect.]]></description>
<pubDate>2022/2/23 16:42:51</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LI Ruiting<sup>1</sup>, LI Liyun<sup>2,3</sup>, SUN Wenqiang<sup>2,3</sup>, DING Jiangsheng<sup>2,3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Ruiting<sup>1</sup>, LI Liyun<sup>2,3</sup>, SUN Wenqiang<sup>2,3</sup>, DING Jiangsheng<sup>2,3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202201006&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preparation and evaluation of protopanaxadiol solid dispersions tablets for improving oral bioavailability]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210006&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  This work intended to report a novel solid dispersion tablet enabling to convert to nanosuspensions for improving the dissolution and oral bioavailability of protopanaxadiol (PPD). <b>Methods</b>  After dissolving PPD, a polymer and a surfactant with a mass ratio of 10:14:6 in ethanol, the solid dispersion was prepared by vacuum drying of the solution. Subsequently, the solid dispersion powders were compressed to tablets, each of which consisted of solid dispersion powders (300 mg), lactose (16 mg), polyvinylpolypyrrolidone (60 mg) and magnesium stearate (4 mg). <b>Results</b>  The results showed that the PPD solid dispersion was converted to a nanosupension upon reconstitution in water. After reconstitution of the solid dispersion consisting of poly(vinyl pyrrolidone-co-vinyl acetate) (PVP/VA) and D-α-tocopherol polyethylene glycol 1000 succinate (TPGS), the nanosuspension with a mean particle size less than 120 nm was obtained and the particle size remained stable for up to 8 h storage. In vitro dissolution data showed that more than 90% of drug in solid dispersion tablets was dissolved within 15 min, markedly higher than ~ 11% of dissolution in the physical mixture tablets of raw PPD material. The drug dissolution state of solid dispersion tablets could maintain at least 8 h. Comparative pharmacokinetic study between solid dispersion and physical mixture tablets was investigated after oral administration to rats. Compared to physical mixture tablets, the maximum plasma concentration and bioavailability of PPD increased by 6.59-fold and 2.54-fold for solid dispersion tablets, respectively. <b>Conclusion</b>  The solid dispersion tablets convertible to nanosuspensions represent as a novel formulation means to improve the dissolution and bioavailability of PPD.]]></description>
<pubDate>2022/11/11 10:33:31</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[LIU Chunyu, ZHAO Yu, LIAO Yonghong, YANG Feifei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Chunyu, ZHAO Yu, LIAO Yonghong, YANG Feifei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210006&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effect of colloidal silica on Moxifloxacin Hydrochloride Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effect of colloidal silica on moxifloxacin hydrochloride tablets. <b>Methods</b>  Different moxifloxacin hydrochloride tablets were prepared by changing the dosage of colloidal silica, the sieving mesh number of colloidal silica, and the mixing time of colloidal silica. By comparing the powder properties of the mixed granules and the dissolution of the tablets. Comprehensive evaluation of the effect of colloidal silica on moxifloxacin hydrochloride tablets. <b>Results</b>  The amount of colloidal silica, the sieving mesh number of colloidal silica, and the mixing time of colloidal silica will all affect the quality of moxifloxacin hydrochloride tablets. <b>Conclusion</b>  Increasing the amount of colloidal silicon dioxide, Reduce the pore size of the screen, and increasing the mixing time will improve the fluidity and compressibility of the mixed granules, increase the hardness of the tablet, and reduce the friability of the tablet. And can accelerate the disintegration of the tablet and improve the dissolution rate.]]></description>
<pubDate>2022/11/11 10:33:31</pubDate>
<category><![CDATA[Formulation Research]]></category>
<author><![CDATA[FU Qingshuang<sup>1</sup>, GAO Yanling<sup>2</sup>, WEI Yanjun<sup>1</sup>, DU Zikun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FU Qingshuang<sup>1</sup>, GAO Yanling<sup>2</sup>, WEI Yanjun<sup>1</sup>, DU Zikun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210007&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>